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ABSTRACT
Background
Adipose tissue (AT) is not only a store of energy but an endocrine organ with capacity to 
produce and release proinflammatory mediators into the circulation. Obesity is an inflammatory 
disease, with increased circulating levels of interleukin (IL)-6, due to synthesis in AT. As 
current knowledge regarding AT inflammation, to a great extent relies on studies done in non-
stimulated or chronic inflammatory conditions, it is important to add data from human studies, 
using different models of induced acute systemic inflammation. As obesity is becoming a global 
disease it is also an increasing risk factor for cardiovascular disease (CVD). CVD events are 
known complications after surgery and severe infection. The mechanisms behind this increased 
risk are still poorly understood but an acute systemic inflammation is a common denominator.
Methods and results
Study I: We investigated if a standardised systemic inflammation, induced by a vaccination 
against Salmonella typhi, would trigger inflammatory gene expression in AT. Healthy volunteers 
were investigated whereof half of them were vaccinated. Plasma levels of IL-6 increased 8 hrs 
after vaccination. In peripheral blood mononuclear cells we found an increased tumour necrosis 
factor gene expression after 4 hrs. In AT there were no differences in gene expression between 
the two groups.
Study II: Gene expression and production of inflammatory mediators in different AT depots 
were investigated after open heart surgery. Plasma levels of IL-6 increased 25-fold. In both 
omental and subcutaneous AT, we found a strong upregulation of nuclear factor-κB regulated 
genes. Immunohistochemistry (IHC) showed staining for E-selectin associated with a high 
number of macrophages in close contact with and in the vascular wall. Increased levels of IL-6 
were detected in microdialysate from subcutaneous AT.
Study III: Plasminogen activator inhibitor-1 (PAI-1) synthesis in AT was studied after acute 
systemic inflammation, induced by open heart surgery. Gene expression of PAI-1 increased 
27-fold in omental AT and 3-fold in subcutaneous AT. After surgery, IHC staining showed 
localization of PAI-1 antigen within endothelial cells, in the AT interstitium close to AT vessels 
and in solitary cells between the adipocytes. The upregulated gene expression and protein 
synthesis in AT was followed by increased concentrations of PAI-1 antigen in plasma.
Study IV: This was a sub-study of study I and II, with the aim to investigate the effects of 
an acute systemic inflammation on adiponectin and leptin synthesis. Neither plasma levels of 
adiponectin nor leptin were changed after vaccination. Gene expression of adiponectin and 
leptin were unaltered in both omental and subcutaneous AT after surgery.
Conclusion
Vaccination stimulates a mild systemic inflammation but does not trigger proinflammatory gene 
expression in AT. Open heart surgery induced a strong inflammatory response in both omental 
and subcutaneous AT including adhesion of macrophages to an activated endothelium and 
release of IL-6 from AT interstitium. We found no evidence that an acute systemic inflammation 
could affect synthesis of adiponectin or leptin indicating that these two adipokines are not key 
elements in the early acute-phase response. There was a markedly increased gene expression 
and protein synthesis of PAI-1 in human AT after open heart surgery. The increase was most 
prominent in omental AT. PAI-1 synthesis in AT, following acute systemic inflammation, may 
be the link between inflammation and impaired fibrinolysis that might explain the increased 
risk for myocardial infarction after surgery or infection.
Adipose tissue inflammation and coagulation in humans
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SAMMANFATTNING
Bakgrund
Fettvävnad är inte bara en energidepå utan också ett endokrint organ med kapacitet att producera 
och frisätta proinflammatoriska markörer till cirkulationen. Fetma är en inflammatorisk sjukdom 
med kroniskt förhöjda nivåer av interleukin (IL) -6, associerat med en ökad produktion av IL-6 
i fettvävnad. Kunskapen kring inflammation i fettvävnad är till stor del baserad på studier av 
icke stimulerad eller kronisk inflammation varför det är viktigt att tillföra data från humanstudier 
av olika modellsystem för stimulerad akut inflammation. Då fetma ökar i västvärlden är det 
också en växande riskfaktor för hjärt- och kärlsjukdom. Det finns också en ökad risk för akut 
hjärtinfarkt efter kirurgi och infektion. De bakomliggande mekanismerna till denna ökade risk 
är ofullständigt kända men en akut systemisk inflammation är en gemensam nämnare.
Metoder och resultat
Studie I: Vi undersökte om en standardiserad systemisk inflammation, stimulerad av en 
vaccination mot Salmonella typhi kunde aktivera inflammation lokalt i fettvävnad. Friska 
frivilliga försökspersoner undersöktes varav hälften blev vaccinerade. 8 timmar efter vaccination 
fann vi ökade nivåer av IL-6 i plasma. I perifera mononukleära vita blodkroppar fann vi ett ökat 
genuttryck av tumour necrosis factor efter 4 timmar. I fettvävnad fann vi ingen skillnad mellan 
grupperna avseende det proinflammatoriska genuttrycket.
Studie II: Här undersöktes genuttryck och produktion av proinflammatoriska markörer i 
underhudsfett och visceral fettvävnad, stimulerat av öppen hjärtkirurgi. Efter kirurgi fann vi 
25 ggr ökade nivåer av IL-6 i plasma. Både i visceral fettvävnad och i underhudsfett fann vi ett 
starkt ökat genuttryck av gener reglerade av den signalväg som styrs av ”nuclear factor κB”. 
Färgning med immunohistokemi visade E-selectin tillsammans med ett stort antal makrofager i 
och intill kärlväggen. Vi fann även ökade nivåer av IL-6 i mikrodialysat från underhudsfett.
Studie III: Syntes av plasminogen activator inhibitor-1 (PAI-1) i fettvävnad studerades efter 
akut systemisk inflammation, stimulerad av öppen hjärtkirurgi. Genuttrycket av PAI-1 ökade 
27 ggr i visceral fettvävnad och 3 ggr i underhudsfett. Efter kirurgi visade immunohistokemisk 
infärgning ett starkt uttryck av PAI-1 protein i endotelceller, mellan fettceller, i närheten av 
kärl och i enstaka celler mellan fettcellerna. Det ökade genuttrycket och proteinproduktionen i 
fettvävnad följdes sedan av ökade nivåer av PAI-1 i plasma.
Studie IV: I en sub-studie till studie I och II undersöktes effekterna på produktionen av adiponectin 
och leptin efter en akut systemisk inflammation. Varken plasmanivåer av adiponectin eller leptin 
förändrades efter vaccination. Genuttrycken av adiponectin och leptin förblev oförändrade i 
både visceral fettvävnad och underhudsfett efter öppen hjärtkirurgi.
Slutsats
Vaccination orsakar en mild systemisk inflammation men påverkar inte genuttrycken för 
proinflammatoriska markörer i fettvävnad. Öppen hjärtkirurgi resulterade i en omfattande 
inflammatorisk aktivitet i fettvävnad, såväl visceralt som i underhud, inkluderande adhesion 
av makrofager till aktiverat endotel i kärlväggen och frisättning av IL-6 från utrymmet mellan 
fettcellerna. Vi fann inga bevis på att en akut systemisk inflammation påverkade syntesen av 
adiponectin eller leptin vilket indikerar att dessa två adipokiner inte har en nyckel-roll tidigt 
under en akut-fas respons. Efter öppen hjärtkirurgi fann vi ett uttalat ökat genuttryck och 
proteinproduktion av PAI-1 i fettvävnad. Ökningen var mest uttalad i visceral fettvävnad. En 
ökad produktion av PAI-1 i fettvävnad kan vara länken mellan inflammation och försämrad 
fibrinolys som kan förklara den ökade risken för hjärtinfarkt efter kirurgi eller infektion.
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INTRODUCTION
General background
Atherosclerosis commonly causes cardiovascular disease (CVD), a major morbidity world-
wide and still the leading cause of mortality in US and Western Europe 1. Conventional risk 
factors for developing CVD are hypertension 2, hypercholesterolaemia 3, diabetes mellitus 4 
and smoking 2, 5. Substantial effort has been made to reduce these risk factors and improve 
treatment of CVD which have resulted in decreased numbers of cardiovascular deaths 1. In 
Sweden between 1986 and 2002, the mortality from coronary heart disease has decreased 
by 53.4% in men and 52.0% in women, mainly due to risk factor reductions 6. Nevertheless, 
an increased prevalence of obesity has occurred during the last decades which is likely to 
undermine the important effort made to prevent CVD 7.
Obesity is the most common nutritional disorder in the industrialized world. Today, more 
than 50% of the adult population in Great Britain and US is overweight (body mass index 
(BMI)≥25) and approximately 30% is obese (BMI≥30) 8. Twenty years ago, only 5% of 
adults in Sweden were obese. Today, around 50% of adult men and 40% of adult women 
are overweight and approximately 10% are obese in both sexes 9. The excess of body fat has 
major consequences on western world morbidity. It is the most potent modifiable factor of 
the metabolic syndrome, characterized by abdominal fat distribution, high blood pressure, 
disturbed lipid metabolism and impaired glucose tolerance. Since obesity is becoming a 
global epidemic, it is also an increasingly important risk factor for CVD 10, 11 and actually, 
also an independent risk factor for developing myocardial infarction 12.
The common denominators of atherosclerosis and obesity extend beyond their overlapping 
incidence and their association to CVD risk factors. They also share common or similar 
pathophysiological pathways; atherosclerosis and obesity are today considered as chronic 
inflammatory processes characterized by activation of both innate and adaptive immunity 13.
Myocardial infarction and its trigger factors
Generally, myocardial infarctions result from coronary atherosclerosis with superimposed 
coronary thrombosis. Myocardial infarctions arise from ruptures of the fibrous cap, which is 
covering the atherosclerotic plaque and is followed by exposure of substances that promote 
platelet activation and thrombin formation 14. Ultimately, this leads to a thrombus that 
interrupts blood flow which results in an imbalance between oxygen demand and supply 
resulting in myocardial necrosis.
Inflammation is crucial in the pathogenesis of plaque instability and therefore also important 
for the development of myocardial infarction. Plasma levels of inflammatory markers such 
as C-reactive protein (CRP) and interleukin (IL)-6 correlate with the clinical course and 
outcome of myocardial infarction 15. There is a circadian variation of myocardial infarction 
with a higher incidence in the early morning which can be explained by a combination of 
sympathetic stress, hypercoagulability of the blood and activated platelets 16. Physical activity 
or emotional stress, associated with increased vasoconstriction following sympathetic stress, 
might also trigger plaque disruption and coronary thrombosis 17.
Cardiovascular events are also known complications in up to five percent of patients undergoing 
non-cardiac surgery 18. Furthermore, there is a five-fold increased risk of myocardial infarction 
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during the first week after a severe infection 19, 20. The mechanisms behind this increased 
risk for myocardial infarction after surgery or infection are still poorly understood but acute 
systemic inflammation is a common denominator.
Atherosclerosis and plaque rupture
Development of atherosclerosis is initiated by activation and dysfunction of endothelial 
cells in individuals with signs of systemic inflammation and/or known risk factors for CVD. 
Dysfunctional endothelial cells cause leukocyte and platelet adhesion to damaged endothelium, 
Figure 1a. An increased permeability of the endothelial cells increases accumulation of lipid 
components, such as low density lipoprotein (LDL) to migrate into the subendothelial space. 
Monocytes, recruited to the intima become loaded with oxidized LDL and accumulate in the 
vessel wall and transform into foam cells which results in the formation of fatty streaks 21. 
The development from fatty streaks to atherosclerotic plaques follows further accumulation 
of inflammatory cells and lipid components that is surrounded by smooth muscle cells and 
collagen-rich matrix. The inflammatory cells are represented by macrophages, mast cells 
and T-cells 22, 23, Figure 1b. Extended progression of the plaque results in a stenosis that 
narrows the artery lumen and affects the blood flow. The central core of the plaque can 
become necrotic and neovascularization may result in leaking of blood and haemorrhage 
which also contribute to plaque progression, Figure 1c. Normally, the atherosclerotic process 
takes many years to develop and over time, the plaque cells secrete matrix-degrading 
proteases and cytokines that results in a thinning of the fibrous cap that covers the plaque and 
prevents that pro-thrombotic materials from inside the plaque get in contact with circulating 
blood. In unstable plaques, a further thinning of the cap will make it to split up, causing 
plaque rupture. Plaque rupture, which is detectable in 60-70% of cases of acute myocardial 
infarctions 24 is dangerous because it exposes the pro-thrombotic contents from inside the 
plaque to circulating blood which results in activation of the coagulation system and finally 
a thrombosis in the artery. Ultimately, the thrombosis causes artery occlusion which prevents 
blood flow and results in a myocardial infarction, Figure 1d 15, 25.
Clinical studies as well as experiments on animal models and in cell cultures have all 
contributed to the understanding of the atherosclerotic process. Often our knowledge about 
pathophysiology on a molecular level rests on animal or in vitro experiments but of course 
these findings need to be reproduced, if possible with investigations on human tissues in vivo. 
Mice do not develop atherosclerosis under normal conditions but genetically modified animals 
with deletion of the gene encoding for apolipoprotein E (Apo-E knockout mice) develop 
hypercholesterolaemia and spontaneous atherosclerosis. Studies on hypercholesterolaemic 
mice have described that the infiltration of LDL into the arterial intima starts an inflammatory 
response 26. Another interesting finding from mice models is that inhibition of platelet 
activation reduces leukocyte infiltration and atherosclerosis in Apo-E knockout mice 27. 
However, this has not been described in humans.
In response to hypercholesterolaemia activated endothelial cells upregulate vascular-cell 
adhesion molecules 1 (VCAM-1) and circulating monocytes and lymphocytes that express 
VCAM-1 receptors on their surface, adhere to these sites on the endothelium. Once these 
circulating white blood cells are attached to the vessel wall, chemokines produced in the 
intima, stimulate them to migrate through the endothelial cell layer and into the subendothelial 
space. Furthermore, results from mice models have demonstrated that pharmacological 
inhibition of these chemokines and adhesion molecules blocks atherosclerosis 28, 29.
Mattias Ekström
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Not only innate but also the adaptive immune response is central in atherosclerosis and T-cell 
infiltrates are always present in atherosclerotic lesions. Exposure of monocytes/macrophages 
to oxidized LDL results in T-cell activation 30. The majority of these activated T-cells 
differentiate into Th1 effector cells which produce the macrophage activating cytokine 
interferon  (INF) -γ. INF-γ activates macrophages and vascular cells resulting in vascular 
inflammation. The process is modulated by regulatory T-cells by producing anti-inflammatory 
cytokines. All these processes induce atherosclerosis and depletion of INF-γ has been shown 
to inhibit the development of atherosclerosis in animal studies 15.
Inflammatory cytokines such as tumour necrosis factor (TNF) and IL-1β are synthesized in 
atherosclerotic plaques and induce substantial production of IL-6. IL-6, in turn stimulates the 
Figure 1. Evolution of atherosclerosis. a) Endothelial cell dysfunction and activation un-
der pro-inflammatory conditions of hyperlipidaemia leads to early platelet aggregation 
and leukocyte adhesion and increased permeability of endothelium. b) Monocytes accu-
mulate lipids and transform into macrophages or foam cells, which result in fatty streaks. 
c) Apoptosis of macrophages and smooth muscle cells creates a necrotic core, and a 
fibrous cap. Neovascularization within the plaque and from the adventitia can result in 
haemorrhage. d) Thinning of the fibrous cap, ultimately leads to plaque rupture with re-
lease of debris, activation of the coagulation system and plaque thrombosis of the artery. 
This results in arterial occlusion and myocardial infarction or stroke.
Reprinted by permission from Macmillan Publishers Ltd: Nature reviews Immunology, 
Weber C et al, copyright 2008.
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liver to produce amounts of acute phase reactants such as CRP. Although all these cytokines 
are important in each step of the pro-inflammatory response the upregulation of CRP makes 
it particularly useful as a clinical marker of atherosclerosis 31.
Adipose tissue and inflammation
The pro-inflammatory cytokines are also synthesized in adipose tissue (AT), thereby 
contributing to the low-grade chronic inflammation seen in obese individuals. Interestingly, 
in this way, there is a cross-talk between inflammation and metabolism.
Traditionally, AT is thought to merely represent a passive store of energy. However, recent 
research has proved AT to be a highly metabolically active organ, also related to several 
risk factors for atherosclerosis and CVD. Obesity has been shown to exhibit multiple 
manifestations of inflammation where AT is an endocrine organ with capacity to produce and 
release proinflammatory active mediators into the circulation.
Adiponectin and leptin are two adipokines primarily synthesized by adipocytes. Adiponectin 
has anti-inflammatory and anti-atherosclerotic activity 32. Furthermore, adiponectin has 
important metabolic effects in obesity, including improvements on endothelial function 
and insulin resistance 33. Consistent with these findings both obesity and CVD have been 
described with decreased circulating levels of adiponectin 34, 35.
Leptin was one of the first hormones isolated from AT and it plays a central role in the regu-
lation of energy expenditure. Knock-out mouse models lacking the gene encoding for leptin 
have been demonstrated to have increased BMI. The supply of leptin to these mice decreased 
their intake of calories 36. Leptin regulates food intake through signalling in hypothalamic 
centres of the brain and leptin has now been established as an AT produced hormone with 
major impact on BMI, energy regulation and insulin resistance 37. In addition, leptin has been 
associated with the inflammatory markers IL-6 and CRP indicating an interaction with the 
acute inflammatory response 38.
AT generates an inflammatory setting, characterized by high levels of CRP and other 
important inflammatory bio-markers, e.g proinflammatory cytokines and adhesion molecules. 
Obesity has been associated with increased unstimulated levels of TNF, IL-6 and vascular 
adhesion molecules, such as VCAM-1 39, 40. TNF is synthesized by adipocytes and might have 
paracrine effects on AT. Moreover, local synthesis of TNF by adipocytes is elevated in obese 
subjects 39, 40. The association between AT and inflammation has further been elucidated by 
demonstrating an in vivo release of IL-6 from human AT 41 and it has been estimated that 
approximately 30% of total circulating IL-6 is produced by AT 42. The AT inflammatory 
milieu is further demonstrated by increased levels of IL-6 in the circulation, due to increased 
expression and synthesis of proinflammatory cytokines in AT 13, 43, 44.  Also, increased gene 
expression of CRP has been found in AT in patients with chronic inflammatory diseases 45.
Interestingly, a prospective study has demonstrated a marked reduction in circulating levels 
of CRP in patients undergoing weight loss surgery 46 and weight loss is also associated to 
decreased AT macrophage infiltration 47. Furthermore, weight reduction in obese subjects 
resulted in decreased levels of inflammatory cytokines and adhesion molecules why it appears 
that weight loss also reduce CVD risk 48, 49.
Ex vivo experiments using human cultured adipocytes stimulated by lipopolysaccharides 
(LPS), have demonstrated an induction of the nuclear factor κB (NF-κB) regulatory pathway 
50, 51. Furthermore, LPS has also been found to induce AT inflammation in vivo demonstrated 
by increased gene expression of inflammatory mediators in subcutaneous AT 52-54. However, 
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since current knowledge about acute AT inflammation mainly rests upon ex vivo studies or 
LPS-stimulated subcutaneous AT inflammation, studied on a gene expression level, further in 
vivo studies including other stimuli of inflammation with a focus on both gene expression and 
protein production in omental and subcutaneous AT, are needed to get a better understanding 
of how AT inflammation is activated in response to an acute systemic inflammation.
Innate immunity
A successful immune response relies on complex interactions between different immune 
cells. These interactions are mediated by a group of soluble peptides called cytokines. The 
term interleukin (IL) is used for cytokines that are secreted by, and act on leukocytes. The 
chemokine family consist of peptides important for the regulation of leukocyte trafficking 
and the migratory behaviour of leukocytes into subendothelial tissues. Other chemokines are 
needed for adhesion and leukocyte activation.
Traditionally the immune system has been divided into adaptive and innate components. 
Adaptive immunity is mainly structured around two classes of specialized lymphocytes, 
B-cells and T-cells. Clonal expansion of lymphocytes in response to an infection is necessary 
for an efficient immune response. However, it takes three to five days to produce sufficient 
numbers of clones which can differentiate into effector cells for specific targets and to develop 
an immunological memory which recognizes and prevents a later infection with the same 
microorganism. This delay leaves time enough for pathogens to damage the host.
In contrast, the rapid mechanisms of innate immunity are activated immediately, within four 
hrs after infection or tissue injury hereby making it possible to quickly inhibit and control the 
invading pathogen 55, 56.
In the next pages I will focus on presenting immune cells, cytokines and chemokines that are 
relevant, to my studies.
Innate immunity refers to the first line of defence that limits infectious challenge in the very 
early stages after pathogen exposure. The ability to recognize and limit infectious challenge 
is mediated by pre-existing molecular and cellular mechanisms that distinguish common and 
frequently encountered pathogens. There are different anatomical levels where the innate 
immune components act to protect against pathogen invasion. For instance, the first line 
of defence is the barrier that consists of epithelial cells in skin and mucosa which serves as 
an effective wall against pathogenic microbes. If the pathogens cross this barrier they are 
efficiently removed and destroyed by immune cells that are operating in underlying tissues. 
One of the most ancient immune defence line, the ability to produce antimicrobial peptides, 
lies within this part of innate immunity, actually found both in plants and animals and therefore 
predate the separation of these two evolutionary lineages 57. Macrophages and neutrophils 
produce toxic products that efficiently kill microbes. Most important of these are nitric oxide 
(NO). Moreover, these cell types also transform O2 into highly reactive forms, called reactive 
oxygen species (ROS), such as superoxide anion (O-) and hydrogen superoxide (H2O2) 
58. 
ROS, in turn, is able to activate the NF-κB signalling pathway 59.
Innate immunity lies behind most inflammatory responses through interactions with the targets 
of innate immune recognition, which are conserved molecular patterns, called pathogen-
associated molecular patterns (PAMPs), such as LPS or damage-associated molecular 
patterns (DAMPs). The acute inflammatory response is triggered in the first instance by the 
innate immune receptors of macrophages, polymorphonuclear leukocytes and mast cells. The 
adaptive immune system completes the innate immune response with specific recognition 
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of proteins, carbohydrates, lipids or nucleic acids, using the same activated effector cells as 
were generated during the innate immune response. In this way the two systems are linked 
to each other 55, 60.
Rolling and extravasation of leukocytes
The recruitment of leukocytes is one of the most important steps of innate immunity. This 
process is mediated by cell-adhesion molecules, expressed on the surface of endothelial cells 
at the site of infection or inflammation in local blood vessels, mainly veins. The selectins 
are induced on activated endothelium and initiate interactions with leukocytes by binding to 
ligands on the surface of circulating leukocytes. This reaction does not anchor the leukocytes 
to the vessel wall but makes them rolling along the endothelium. Next, the rolling leukocytes 
bind to intercellular adhesion molecules (ICAMs) on the endothelial surface, resulting in a 
tighter adhesion to the vessel wall. The activation of endothelium is driven by interactions 
between cytokines produced by macrophages, in particular TNF and a release of preformed 
P-selectin that will be expressed on the endothelial surface. In addition, mRNA encoding 
for E-selectin is upregulated and within two hrs the endothelial cells are expressing mainly 
E-selectin on their surface 61.
When the leukocytes have stopped their rolling movement along the endothelium, further 
interactions with integrins, allows them to squeeze between the endothelial cells into the 
subendothelial tissue. Finally the leukocyte migrates along the gradient of chemokines, such 
as chemokine ligand (CCL)-2 and IL-8/CXCL8, Figure 2.
Figure 2. Monocytes circulating in the blood vessel (mainly veins) recognize blood vessel 
walls near the site of inflammation and leave the bloodstream, to migrate into the tissue 
toward the site of infection or inflammation.
©2005 From Immunobiology 6E by Janeway et al. Reproduced by permission of Garland 
Science/Taylor and Francis LLC.
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CCL-2, primarily acts on monocytes and induce their differentiation to macrophages on their 
migration from circulating blood to the site of infection and inflammation 62. CXCL8 was the 
first chemokine to be described and has similar functions as CCL-2 but act more specifically 
on neutrophils by attracting them to leave the blood stream 63.
In the subendothelial space the pathogen is recognized and eliminated by mononuclear 
phagocytes, the macrophages that are essential cells in the immune system. Macrophages 
differentiate continuously from monocytes that leave the circulation to migrate into the 
surrounding tissue, as described above. They are able to recognize pathogens through their 
surface receptors and discriminate between self from non-self. One of these receptors is the 
cluster of differentiation (CD)14, a receptor that binds to LPS and is predominantly found on 
monocytes and macrophages. The LPS: CD14 complex in turn, triggers the membrane protein 
toll like receptor (TLR)4 which activates the nuclear factor (NF) κB signalling pathway 
resulting in production of pro-inflammatory cytokines and chemokines 56, 64.
NF-κB signalling pathway
It is well established that activation of the NF-κB signalling pathway is essential for regulating 
immune responses and is implicated in many inflammatory diseases. However, inhibition of 
this important regulatory pathway is not a solution or even a possible way to treat inflammatory 
diseases. In mouse models, total inhibition of NF-κB in non-immune epithelial cells results in 
severe and mortal inflammatory conditions 65, 66. This, apparently paradoxical finding, focus 
on the multi-disciplinary roles of NF-κB signalling and suggests that inhibition of NF-κB in 
certain tissues might have pro-inflammatory effects by disrupting the physiological immune 
balance 64.
The NF-κB dimers consist of a complex of RELA (also known as p65) and p50. In resting 
cells, the NF-κB complex is associated with inhibitory peptides and is sequestered in the 
cytoplasm. Activation of NF-κB is controlled by the IκB kinase (IKK) complex and NEMO, a 
regulatory subunit (NF-κB-essential modulator). Pro-inflammatory signals stimulate receptors 
of the tumour necrosis factor receptor (TNFR) or IL-1/Toll-like receptor (TLR) super families, 
which activate the IκB kinase (IKK) complex. IKK, in turn phosphorylates IκB which starts 
a polyubiquitylation and a subsiding degradation of IκB. Hereafter, when IκB is removed, 
the NF-κB dimer (p50 and p65) is allowed to migrate into, and to accumulate in the cell 
nucleus where it binds to target genes and activates transcription. In this way, NF-κB is able 
to translate upstream signals into a rapid onset of gene expression. Mainly, NF-κB regulates 
genes with pro-inflammatory effects but also genes encoding for inhibition of apoptosis. 
These molecules are central in the innate immune response to fight invading pathogens and 
are required for migration of inflammatory cells to tissue areas where the NF-κB has been 
activated in response to infection or injury, Figure 3 64.
IL-1β, IL-6 and TNF
IL-1β, IL-6 and TNF are pro-inflammatory cytokines controlled through the NF-κB regulatory 
pathway. They are characterized as being endogenous pyrogenes as they derive from 
endogenous sources in contrast to exogenous pyrogenes such as LPS that derives from bacterial 
components. They act on hypothalamus to alter the body temperature, and on muscles and AT 
to mobilize energy to increase body temperature. In conditions with fever both bacterial and 
viral replication are decreased whereas the adaptive immune system operates more efficiently. 
One of the most important effects of these three cytokines is the initiation of an acute-phase 
response which follows the action of IL-1β, IL-6 and TNF on hepatocytes. During an acute-
phase response levels of some plasma proteins increase markedly and one crucial acute-phase 
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protein is CRP, a member of the pentraxin protein family which bind to certain bacteria and 
fungal cell walls. By binding to invading pathogens it enables phagocytosis by opsonization 
but it also activates the component cascade, another important part of the innate immune 
system that is not going to be further described in detail here.
Figure 3. Schematic description of the classical NF-κB signalling pathway.
IkB kinase - IKK; NF-κB essential modulator - NEMO; Nuclear factor-κB - NF-κB; Toll-like 
receptor - TLR; Tumour necrosis factor receptor - TNFR; 
Reprinted by permission from Macmillan Publishers Ltd: Nature reviews Immunology, 
Pasparakis M, copyright 2009.
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IL-1β is produced by several cell types including monocytes, macrophages, dendritic cells 
and epithelial cells. Mediators that initiate IL-1β synthesis are PAMPs and pro-inflammatory 
cytokines including TNF. It also activates bone marrow epithelium to release neutrophils. 
The signals mediated by IL-1β result in down stream up-regulation of genes encoding pro-
inflammatory chemokines and cytokines.
IL-6 is a multifunctional cytokine with an important role in host defence but its role as an 
inflammatory cytokine depends on whether there is an ongoing acute immune response or 
not. It is involved in the development of cells and tissues as well as in different pathological 
conditions 67, 68. IL-6 is not constitutively produced but can be synthesized in response to 
inflammatory stimuli such as IL-1β, LPS and TNF 69, 70. Glucocorticoids, in turn, suppress 
IL-6 expression in a variety of cell types 71. However during stress and acute inflammation, 
glucocorticoids can also synergize with IL-6 and induce hepatocytes to produce acute phase 
proteins 72.     
Furthermore, IL-6 has been shown to be released in significant amounts from skeletal muscle 
during exercise 73, 74. Interestingly, the IL-6 derived from muscle during exercise differs from 
the cytokine response to sepsis with regard to TNF, since the cytokine response to exercise 
is not preceded by an increase in plasma TNF 74. Monocytes/macrophages are not involved 
in the IL-6 production in skeletal muscles since no upregulation of  IL1β, IL-6 or TNF gene 
expression has been demonstrated in these cells during exercise 75. The biological importance 
of IL-6 synthesis in skeletal muscles during exercise might have other but immunological 
functions. One theory is that it acts as an endocrine signal indicating that the muscle glycogen 
store has reached critically low levels.
Moreover, IL-6 may have beneficial effects on the metabolism of carbohydrates and fat as well 
as exercise capacity 74. Experiments on animals have demonstrated a preventing mechanism 
on obesity by IL-6 76. This mechanism is not fully understood but IL-6 might have effects on 
leptin sensitivity. Then the site of action would be in the hypothalamus where it stimulates the 
synthesis of adrenocorticotropic hormone (ACTH), thereby activating a negative feedback 
loop of inflammation and a link to the neuroendocrine system 76, 77.
IL-6 is produced by many different cell types including adipocytes, endothelial cells, 
fibroblasts, monocytes/macrophages and myocytes. In an immune response IL-6 regulates 
production of adhesion molecules involved in the release of other cytokines and induces 
the hepatic synthesis of CRP, as mentioned above. In vivo release of IL-6 from human AT 
has been demonstrated 41 and in addition, positive correlations between both circulating and 
AT levels of IL-6, TNF and serum CRP levels have been shown 44. The various effects of 
IL-6 are mediated through a receptor complex consisting of a glycoprotein (gp130) and its 
transmambrane receptor (IL-6R) or its soluble receptor (sIL-6R) 78, 79. The gp130 has been 
found to function as a receptor component for several cytokines other than IL-6. It can be 
found in almost all tissues and cells which explain the pleiotropy of IL-6. IL-6R is mainly 
expressed on hepatocytes and different subsets of leukocytes.
Recent research provides growing evidence of a pathological role of IL-6 in various diseases, 
such as inflammatory or auto-immune diseases. Based on these findings, a new therapeutic 
approach to block IL-6 with monoclonal antibodies against IL-6R in rheumatoid arthritis has 
been developed 67.
TNF is synthesized by cells of the immune system and is a strong mediator of inflammatory 
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and immune functions 68. Macrophages in AT can produce TNF shown to be associated to 
proinflammatory activity that may contribute to atherosclerosis 37. Circulating levels of TNF 
are usually very low during healthy conditions but increase rapidly during an infection or an 
inflammation 80. TNF launches several downstream pro-inflammatory effects and mediates the 
expression and synthesis of adhesion molecules as E-selectin on vascular endothelium which 
together with chemokines contribute to the recruitment of leukocytes to the site of infection 
or inflammation. However, uncontrolled this crucial chemokine can cause vasodilatation and 
increased vascular permeability, leading to loss of circulating plasma volume and eventually 
to shock during sepsis.
Fibrinolysis and plasminogen activator inhibitor-1
Fibrinolysis is a cascade of enzymatic processes leading to degradation of fibrin. This process 
is determined by both plasminogen activators and inhibitors, whereof plasminogen activator 
inhibitor (PAI) 1 is believed to be the most important inhibitor. PAI-1 decreases fibrinolytic 
activity by acting as an inhibitor of both urokinase-type plasminogen activator (uPA) and 
tissue plasminogen activator (tPA). Inhibition of plasmin by PAI-1 results in inadequate 
fibrinolytic activity which may result in the formation of a vascular thrombosis. Hepatocytes, 
platelets and vascular endothelial cells are believed to be the main producers of PAI-1, but 
the contribution of different tissues to circulating PAI-1 may differ in health and disease 81. 
Furthermore, there is a diurnal variation of plasma levels of PAI-1 with the highest levels 
seen at 6 am in the morning 82.
Increased plasma concentrations of PAI-1 are associated with an increased risk of deep vein 
thrombosis, pulmonary embolism and myocardial infarction 83-85. Previously, an association 
between adiposity and impaired fibrinolysis has been observed 86-88 and obese diabetic 
subjects are reported to have increased circulating concentrations of PAI-1 89. Importantly, 
both murine and human adipocytes have been shown to express PAI-1 mRNA 88, 90, 91.
Other conditions associated with elevated levels of PAI-1 are physical inactivity, 
hyperlipidaemia (especially hypertriglyceridaemia) and the metabolic syndrome 92, 93. PAI-1 
is described as an acute phase protein and increases during infections and acute inflammations 
and high plasma levels during sepsis is associated to poorer prognosis 85. The regulation of 
gene expression of PAI-1 in AT has been investigated in numerous studies. Proinflammatory 
cytokines, such as IL-1β and TNF increase PAI-1 mRNA in AT in animal models 90, 94, 95 
while TNF, IL-1b and IL-6 all stimulate upregulation of PAI-1 gene expression in human 
adipocytes ex vivo 96, 97. Other well-known inducers of PAI-1 synthesis in AT are angiotensin 
II, corticosteroids and insulin whereas catecholamines suppress PAI-1 gene expression and 
synthesis in AT 98-100. The current knowledge regarding regulation of PAI-1 in AT is based on 
animal studies or ex vivo experiments on human adipocytes. However, it is unclear whether 
human adipocytes cultured ex vivo adequately represent the situation on a tissue level in vivo. 
So far, no study has described stimulated gene expression and protein synthesis of PAI-1 in 
vivo in human AT (Figure 4).
In vivo models of induced inflammation in humans
To investigate the effects of an acute systemic inflammation on different organs and tissues in 
humans, several models of induced inflammation have been used, Figure 5.
One way to stimulate a mild but systemic inflammation is the use of a commercially vaccine 
against Salmonella typhi, previously shown to cause endothelial dysfunction and activate 
coagulation 101-103. Furthermore, this model has been used to demonstrate protective actions 
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of aspirin on inflammation-induced endothelial dysfunction 104. Vaccination is a safe model 
without any major side effects and results in 2-4-fold increased plasma levels of IL-6 
after 8 hrs 101, 105. The clinical relevance of vaccination has been discussed in the context 
of infection or inflammation as a trigger of myocardial infarction, but there has not been 
found any increased risk of a myocardial infarction after influenza, tetanus or pneumococcal 
vaccinations 19.
Previously, a mild but systemic inflammatory response has been reported after a percutaneous 
coronary intervention (PCI) according to a standard procedure. PCI results in doubled plasma 
levels of IL-6 after six hrs 106. In addition, this inflammatory response is of clinical relevance 
since the increase in CRP is associated with the risk of new coronary events 107.
Another, non drug-induced experimental model of inflammation is periodontal therapy, 
where the mechanical removal of the biofilm and subgingival calculus deposits in order to 
reduce bacterial load and local inflammation, results in a 3-4-fold increase in plasma levels 
of IL-6 one day after therapy. Further, it causes endothelial dysfunction and has procoagula-
tive effects 108-110.
Open heart surgery with cardiopulmonary bypass (CPB) is one of the strongest models of 
induced inflammation found in daily clinic. Open heart surgery results in an extensive acute 
systemic inflammation with a 30-40-fold increase in plasma levels of IL-6, 2-6 hrs after 
tPA
tPA
Plasminogen
Plasminogen Plasmin
Plasmin
Fibrinolysis
Thrombosis
Obesity
Ang II
LP(a)
TNF
Insulin
PAI-1
Figure 4. The normal balance between thrombosis and fibrinolysis is determined by tis-
sue plasminogen activators (tPA) and their inhibitors. In obesity there is a relative in-
crease in the levels of plasminogen activator inihibitor-1 (PAI-1) which promotes a pro-
thrombotic state.
Ang II – angiotensin II; lp(a) – lipoprotein (a); TNF – tumour necrosis factor. 
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start of surgery 111, 112. Moreover, open heart surgery results in increased gene expression of 
inflammatory mediators such as IL-1β, TNF, TLR-2 and 4 in circulating leukocytes, pos-
sibly due to contact of circulating blood with the synthetic surface of the CPB system 113, 114. 
The activation of the acute phase response due to open heart surgery and CPB is a complex 
process. Possibly there are different triggers: the surgical trauma itself, blood contact with 
non physiological surfaces as mentioned above, endotoxemia and ischemia 115. This inflam-
matory response may contribute to several postoperative complications including myocardial 
dysfunction, bleeding disorders, respiratory failure and multiple organ failure.
To my knowledge, injection of a single bolus dose of endotoxin or LPS is the strongest 
experimental model of inflammation. This model has been used in animal and human studies 
for many years to investigate the relationships between infection and the acute-phase response 
in the host 116-118. A bolus injection of LPS (2 ng/kg) results in a 300-fold increase in plasma 
levels of IL-6 2 hrs after LPS challenge 119. The expected side-effects due to LPS are mild and 
transient flu-like symptoms.
Single dose of LPS (2 ng/kg intravenously)
- a 300 fold increase after 2 hrs
Open heart surgery with CPB 
- a 30-40 fold increase after 2-6 hrs
Peridontitis therapy
- a 3-4 fold increase after 24 hrs
Vaccination (S. typhi)
- a 2-4 fold increase after 8 hrs
Percutaneous coronary intervention
- a 2 fold increase after 6 hrs
Pl
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m
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Figure 5. In vivo models of induced systemic inflammation in humans, and their effects on 
plasma levels of IL-6.
CPB – cardiopulmonary bypass, IL-6 – interleukin-6: LPS – lipopolysaccharide; S. typhi – Sal-
monella typhi. 
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AIMS
The overall purpose of this thesis was to further investigate and to better understand if and 
how AT inflammation is initiated following an acute systemic inflammation in humans. In 
addition, potential mechanisms behind the increased risk of a myocardial infarction following 
an acute systemic inflammation have been investigated.
The major hypothesis is that an acute systemic inflammation in humans induces inflammatory 
activity in AT in vivo. A second hypothesis is that an acute systemic inflammation, through 
the activation of AT inflammatory capacity, induces gene expression and protein production 
of PAI-1 in AT.
The specific aims are:
- to investigate if a standardised inflammatory stimulus, using vaccination against I. 
S. typhi as a model of inflammation, would trigger inflammatory gene expression 
in AT.
- to analyze the II. in vivo gene expression and production of inflammatory mediators, 
focusing on innate immunity, in both omental and subcutaneous AT in patients 
undergoing open heart surgery with cardiopulmonary bypass.
- to study the plasminogen activator inhibitor-1 synthesis in AT stimulated by acute III. 
systemic inflammation, induced by open heart surgery.
- to examine the effects of an acute systemic inflammation, induced by vaccination IV. 
against S. typhi or open heart surgery respectively, on adiponectin and leptin 
synthesis.
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MATERIALS AND METHODS
Study subjects
In this thesis two study groups have been investigated: the vaccination study group and 
the open heart surgery study group. The distribution of the subjects from these two groups 
between paper I-IV is described in detail in Figure 6a.
The investigations were made in accordance with the declaration of Helsinki and all subjects 
gave informed written consent to participate in the studies which were approved by the Ethics 
Committee of the Karolinska Institutet.
The vaccination study group (paper I and IV)
The vaccination study group comprised of eighteen healthy volunteers (16 men and 2 post-
menopausal women) and all subjects were included and examined from May 2006 until June 
2007. They were invited as being participants in two previous studies. One study comprised 
387 healthy individuals that served as controls to patients with a first myocardial infarction 
before the age of 60 years, in order to investigate novel risk factors for atherosclerosis and 
myocardial infarction 120. The other study included 96 healthy men in which postprandial 
triglyceridemia were studied in relation to intima-media thickness 121. All together, 74 
individuals were asked to participate but 56 were excluded after a telephone interview because 
of chronic medical conditions or unwillingness to participate. Further exclusion criteria 
were on-going treatment with anti-inflammatory drugs and a history of previous vaccination 
against S. typhi. Basic characteristics and study protocol are described in detail in paper I.
In brief, venous blood samples were obtained after 0, 4, 8, 12 and 24 hrs. After the initial blood 
sample, subjects in the vaccine group received a subcutaneous injection with vaccine against 
S. Typhi. Four hours after the first blood sampling all subjects underwent a subcutaneous fat 
biopsy from the periumbilical area of the abdomen 122 for gene expression studies. At 0 and 4 
hrs venous blood samples were obtained for analysis of gene expression in PBMCs.
To control for differences in inflammatory responses due to different genotypes, all subjects in 
the vaccination study group were homozygous for the common -174 G allele in the -174G>C 
polymorphism in the IL-6 gene.
Vaccination study group
18 subjects
Open heart study group
22 subjects
Study I Study IV Study II Study III
Figure 6a. The distribution of subjects between paper I-IV.
18 18 9 18 22
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The open heart surgery group (paper II, III and IV)
Patients were eligible if they were planned for elective coronary artery bypass grafting 
(CABG) surgery and/or aortic or mitral valve replacement therapy according to a standard 
surgical procedure from May 2008 until December 2009 at the Department of Thoracic 
Surgery at the Karolinska University Hospital, Solna, Sweden. Patients were excluded if 
they had unstable coronary artery disease or were treated with corticosteroids. Twenty-two 
male patients who were planned for open heart surgery underwent blood sampling and/or AT 
biopsies for gene expression and/or immunohistochemistry before and after CPB.
Basic characteristics and study protocols are described in detail in paper II and III.
Methods
All methods are described in detail in each paper. Here follow a brief description of the 
different laboratory methods used.
Plasma analyses
Enzyme-linked immunosorbent assay (ELISA)
Plasma levels of IL-6 in paper I and IV were determined in duplicates using one high sensitive 
ELISA plate (R&D Systems) with an intra-assay coefficient of variation (CV) of 9.5%.
Plasma levels of IL-6 in paper II and III were analyzed in duplicates using one Quantikine 
Human IL-6 ELISA plate (R&D Systems) with an intra-assay CV of 10.2%.
Plasma levels of PAI-1 antigen in paper III were analysed in duplicates using the DuoSet 
ELISA for human Serpine E1/PAI-1 (R&D Systems). Mean intra-assay, respectively inter-
assay CV was 6.5% and 5.1%.
Radio immuno assay (RIA)
Plasma levels of adiponectin and leptin in paper IV were analyzed in duplicates using double-
antibody radio immuno assays (RIA) (Linco). CV for adiponectin was 15.2% at low (2–4 µg/
mL) and 8.8% at high (26–54 µg/mL) levels. CV for leptin was 4.7% at both low (2–4 ng/
mL) and high (10–15 ng/mL) levels.
Adipose tissue biopsies
In paper I and IV all subjects underwent a subcutaneous AT biopsy from the periumbilical 
area of the abdomen, as described 122. The biopsy of 300-500 mg was washed in saline and 
immediately frozen in RNAlater (Ambion) and stored in – 80 C for gene expression studies.
In the open heart surgery group paired AT biopsies of approximately 1 cm3 were taken from 
all together 13 patients. The first 9 patients were investigated in paper II and IV where after 
4 more patients were included for paper III. Both omental and subcutaneous AT biopsies 
were collected from six patients, only omental AT biopsies from one patient and only 
subcutaneous AT biopsies from six patients, see Figure 6b. The AT biopsies were collected 
before institution of CPB and at 15-20 min after removal of the aortic cross-clamp when 
the patient had been weaned off CPB. The omental AT biopsies were taken through a small 
opening to the abdomen in the bottom of the wound and the subcutaneous AT biopsies were 
taken deeply from the side of the median sternotomy incision.
RNA extraction and cDNA preparation
Total RNA was extracted from PBMCs in paper I using QIAamp RNA Blood Mini Kit 
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(QIAGEN). Biopsies from omental and subcutaneous AT in paper I-IV were immediately 
placed in RNAlater (Ambion,) and then frozen at – 80ºC according to the manufacturer’s 
instructions.
Frozen adipose tissue was homogenized and total RNA extracted using the RNeasy Mini 
Kit (QIAGEN) according to the supplier’s instructions including a DNase digestion step 
(RNase-Free DNase set, QIAGEN) to remove any contaminating genomic DNA. An Agilent 
2100 Bio analyzer (Agilent Technologies) was used to confirm the quality of extracted RNA. 
A NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies) was used to analyse 
the concentration of RNA. Three hundred ng of RNA from each sample was transcribed 
to complementary DNA (cDNA) by Invitrogen superscript first strand synthesis system for 
real time polymerase chain reaction (Invitrogen) or by Applied Biosystems cDNA-kit, using 
random primers. RNA and cDNA were stored at -80°C.
Gene expression studies
House keeping genes
A house keeping gene is encoding for a protein that is not affected of the variable studied, in 
this case stable during acute inflammation. House keeping genes are needed to compensate 
for minor differences in RNA concentration and in differed efficiency in the cDNA synthesis 
between the samples. To investigate which house keeping gene to use in the vaccination 
study group, cDNA from PBMCs from four of the subjects was analysed before and four hrs 
after vaccination using TaqMan Human Endogenous Control Plate (Applied Biosystems). 
In the open heart surgery study group cDNA from omental AT from four subjects was 
analysed before and after surgery using TaqMan Human Endogenous Control Plate (Applied 
Biosystems).
As Cyclophylin A demonstrated stability during inflammation and a similar cycle threshold 
value (Ct-value) to many of the genes of interest, it was used for the relative quantification 
(RQ) analyses in both study groups.
RT-PCR
To analyze gene expression of AT biopsies and PBMCs in paper I and III 3 μl of cDNA were 
mixed with TaqMan Universal PCR master Mix (2x) (Applied Biosystems) and primer-probe 
mix (20x) with TaqMan Gene Expression Assays (Applied Biosystems) to a final volume of 
Paper II and IV
7 oment
8 subcut
n=9
Paper III 
7 oment
12 subcut
n=13
6 subcut
6 
oment and 
subcut
1 oment
6
2
1
6
6
1
Figure 6b. The distribution of biopsies from omental and subcutaneous adipose tissue 
between paper II-IV.
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25μl and all samples were run in triplicates. The gene expression assays used for quantitative 
RT-PCR (TaqMan®) are all described in detail in each paper.
To analyze AT gene expression in study II-III, cDNA was mixed with TaqMan® Universal 
PCR master Mix (2x) (Applied Biosystems) in a total volume of 90 μl and all samples were 
run in duplicates. The samples were loaded onto a TaqMan Low Density Assay plate (Applied 
Biosystems). Primers for the target and hose keeping gene expression assays (Applied 
Biosystems) are listed in detail in each paper.
Immunohistochemical staining of adipose tissue sections
The gene expression results were confirmed by immunohistochemistry in paper II and III. 
Immunohistochemical staining was performed on biopsies from omental and subcutaneous 
AT to investigate active NF-κB-p65, the protein of E-selectin (anti-CD62E) and presence 
of macrophages (CD68) in paper II and to investigate staining intensity and localization of 
PAI-1 antigen in paper III.
Staining was performed using a standard protocol on serial sections from 4-5 μm thick 
formalin-fixed paraffin-embedded sections. Following antigen retrieval procedure using heat 
the sections were incubated with primary antibodies, as described in detail in each paper. 
Phosphate buffer saline was used in all subsequent washes. Positive immune reactivity was 
visualized using Avidin-Biotin peroxidase Complex (Vector Laboratories) and developed 
using a DAB-kit (Vector Laboratories) according to the instructions of the manufacturer. 
Sections were counterstained with haematoxylin.
Evaluation of the immunohistochemical staining included only subcutaneous AT where the 
number of positive cells was estimated in relation to the number of vessels in every paired 
biopsy. A semi-quantitative scale from 0 to +++ (where 0 is no positive cells, + is < 25% 
positive cells, ++ is 25-75% positive cells and +++ is > 75% positive cells) was used. The 
evaluation was performed blindly by two independent investigators. The agreement between 
the different investigators was > 90 %. The discrepancy was never more than one scale step 
and consensus was obtained by re-evaluation.
Microdialysis
Microdialysis is a validated method to gain access to and sample tissue derived molecules 
from the intercellular space. In brief, the basic principle is to copy the function of a capillary 
blood vessel by perfusing a dialysis membrane, inserted in the tissue, with a physiological 
liquid. The dialysate could then be analyzed and reflects the composition of the extracellular 
fluid due to the diffusion of substances back and forth over the membrane. Using microdialysis 
enables a continuous sampling for hours to days without withdrawing any blood 123-125, see 
Figure 7. In the studies by Dostolova and Murdolo there have been indicated a risk of an 
artefact due to the trauma from the catheter itself. Possibly, this risk may depend on which 
insertion technique and catheter membrane that was used. To avoid this artefact risk we used 
a two catheter membrane protocol where the second membrane was inserted two and a half 
hrs after the first membrane, assuming that local catheter-induced inflammation would result 
in similar IL-6 dynamics in both catheters.
Local production of IL-6 was studied by microdialysis in subcutaneous AT during open heart 
surgery in four patients, representative for the whole study group regarding age, BMI and the 
CPB-time. At start of surgery a microdialysis catheter (CMA 71, CMA Microdialysis) with 
a 100 000 Da cut-off and a membrane length of 30 mm was inserted subcutaneously under 
sterile conditions in the upper left quadrant of the abdomen without using local anaesthetics. 
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The catheter membrane was inserted guided by a splitable introducer (CMA Microdialysis) 
where after the introducer immediately was drawn back and the catheter membrane was 
left uncovered in the tissue. The catheter was covered with a sterile dressing membrane and 
immediately connected to a microdialysis pump (CMA 107, CMA Microdialysis) and infused 
with Ringer-acetat (Fresenius Kabi) with a flow-rate of 1 μl/min. The dialysate was collected 
at 30 min intervals for 330 min. Collected dialysate up to 60 min after catheter insertion was 
not included in the statistical analysis because of the normal equilibrating and fluid filling 
time period of one hour of the catheter syst 125. The dialysate was collected into microvials 
(CMA Microdialysis) and immediately placed on ice and stored at -80º C.
Dialysate analysis 
Dialysate was analysed for lactate concentrations using a photometric method (ISCUS, CMA 
Microdialysis) and for IL-6 levels using ELISA (Human IL-6 DuoSet, R&D Systems). Intra- 
and inter-assay coefficients of variations were 9.4% and 15.0%, respectively.
Statistical analyses
Data are presented as median (interquartile range), median (min-max), mean ± Standard 
Error of Mean (SEM) or numbers (percent). Differences between groups were compared 
using Mann-Whitney U-test (skewed data), Wilcoxon matched-pairs signed-rank test or 
student’s t-test. A test for linear trend was used to evaluate the differences in plasma levels of 
PAI-1 over time after surgery, in paper III.
Figure 7.  The basic principle of microdialysis is to mimic the capillary blood vessel. A 
dialysis membrane is inserted in the tissue and perfused with a physiological liquid. The 
dialysate could be analyzed, and reflects the composition of the extracellular fluid due 
to the diffusion of substances back and forth over the membrane. Using microdialysis 
enables a continuous sampling for hours to days without withdrawing any blood.
Reprinted by permission from CMA Microdialysis AB.
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To minimize the risk of a type I error due to the limited number of study subjects and multiple 
testing in paper II, only gene expression results were considered significant for genes where 
all samples showed an increased relative quantification after surgery.
A mixed linear model was used to evaluate the effect of microdialysis catheters over time 
on IL-6 in dialysate, in paper II. Time was entered in the model as a categorical variable 
with four different time points and an interaction term was included in the model to test for 
heterogeneous differences between catheters. Because of skewed data and an increase of 
variation with time log transformed IL-6 was used in the final analysis. There is always a risk 
of finding at least one significant difference when doing multiple testing even if the overall 
null hypothesis that none of the variables differ between groups is true. The Bonferroni 
procedure is sometimes used to correct for this. One problem with this method is that it is 
conservative in the usual multivariate situation when the comparisons are not independent. 
In our study with dependent variables it is not desirable to control the error rate of the whole 
study, since this would reduce the power and therefore may miss relevant and significant 
differences.
The level of significance was specified at <0.05
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RESULTS AND DISCUSSION
Paper I
We investigated if a standardised inflammatory stimulus could activate AT inflammation and 
circulating PBMCs, using vaccination against Salmonella typhi as a model of inflammation. 
Since current knowledge about stimulated inflammatory activity in different cell types and 
tissues is mostly based on animal and in vitro studies, it is of particular interest to investigate 
this in humans. Eighteen healthy volunteers were included in the study. Every second subject 
was allocated to vaccine or control group. Gene expression of IL-1β, IL-6 and TNF were 
investigated in AT and PBMCs. Relative quantification of gene expression was calculated 
with cyclophylin A as a house keeping gene.
Systemic inflammatory markers 
No differences were found between the two groups regarding basic characteristics (Table, 
paper I). We found higher plasma levels of IL-6 in the vaccine group 8 hrs after vaccination, 
4.86±9.3 pg/ml compared to 1.6±2.0 pg/ml in the control group (Figure 2, paper I).
Gene expression of inflammatory markers 
Our results demonstrated an increased gene expression of TNF in PBMCs 4 hrs after 
vaccination when compared to the control group, but no differences were found in gene 
expression of IL1-β and IL-6 between the two groups, Figure 8a.
In AT there were no differences in mRNA gene expression of IL1-β, IL-6 or TNF between 
the vaccine and the control group, Figure 8b. The gene expression of IL-6 was higher in AT 
compared to PBMCs and the gene expression of IL-1β was higher in PBMCs compared to 
AT taking vaccinated and controls together. In this context it’s noteworthy that the mRNA 
expression of the house keeping gene was similar in both AT biopsies and PBMCs.
 
Median; Box: 25%-75%; Whisker: Non-Outlier Range Median; Box: 25%-75%; Whisker: Non-Outlier Range
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Figure 8. RNA expression of inflammatory cytokines in (a) peripheral blood mononu-
clear cells (PBMC) and (b) adipose tissue. Indexes of quantitative RNA gene expression of 
interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α) in relation 
to the house keeping gene cyclophylin A. Vaccinated subjects in striped boxes and controls 
in open boxes. 
(a) (b)
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Discussion
The higher plasma levels of IL-6 in the vaccination group support the experimental model of 
systemic inflammation. An increased IL-6 gene expression in PBMCs could however not be 
found 4 hrs after vaccination, perhaps due to kinetics or that the IL-6 producing monocytes 
mainly are differentiating into macrophages and trapped in the tissue at the site of vaccination. 
We found a four-fold increase of circulating IL-6 following vaccination. Previous results 
from our group have shown ten-fold increases after vaccination 126. However, compared to 
the previous study, our subjects did not have an indwelling peripheral vein catheter during the 
study which probably could explain the difference in peak plasma IL-6 levels; otherwise the 
study protocol was similar. Genetic variation is an important factor with possible impact on 
circulating levels of IL-6. However, there have been conflicting data whether genetic variation 
in the IL-6 gene could explain variability in stimulated plasma levels of IL-6 119, 127-129. Results 
from our group have clearly demonstrated that the G-allele of the -174 G>C polymorphism in 
the promoter region of the IL-6 gene is associated with increased IL-6 levels in plasma after 
vaccination 126. Trying to control for genetic differences, all subjects were homozygous for the 
common -174 G allele.
Although vaccination is not believed to result in increased plasma TNF levels 101, 126, we found 
an increased gene expression of TNF in PBMCs 4 hrs after vaccination when compared to 
the control group but no differences regarding gene expression of IL1-β and IL-6 between 
the two groups. The reason for these apparently divergent findings is not fully understood 
but a possible explanation is that the increased TNF gene expression in PBMCs found in the 
present study derives from a subset of activated monocytes/macrophages released from the 
vaccinated tissue. This increase of TNF gene expression might not be substantial enough to 
result in increased plasma levels of the protein. However, according to our results TNF is a 
more relevant stimulus than IL-1β in stimulating IL-6 thereby extending previous studies in 
animals and in vitro 68.
Human subcutaneous AT can release IL-6 in vivo 41. Our results are in agreement with this 
finding by demonstrating unstimulated IL-6 gene expression in AT. Interestingly, the basal 
level of mRNA gene expression was four-fold higher in AT compared to PBMCs. However, 
we were not able to stimulate AT by vaccination. In contrast, there seems to be an increased 
transcription of IL-6 mRNA in human adipocytes following ex vivo LPS stimulation 130. 
Furthermore, patients with chronic inflammation have increased IL-6 gene expression in 
AT compared with patients with normal levels of inflammatory markers 45, suggesting that 
AT actually responds to an inflammatory stimulation. Further in vivo studies with stronger 
stimulus to inflammation are needed to resolve this issue.
We chose to collect AT biopsies only once, at 4 hrs and we cannot exclude that AT biopsies at 
other time-points would have generated a different result. The time point was chosen because 
of experiences from an earlier study in our group that had shown increasing circulating IL-6, 
4 hrs after vaccination 126. The reason for taking biopsies only once was that we wished to 
avoid the risk of an uncontrolled systemic inflammation due to the local trauma caused by 
the biopsy. This step of precaution led us to compare vaccinated subjects with non-vaccinated 
instead of using subjects as their own controls which would have reduced the risk of inter-
individual variation to a minimum. Although the biopsy did not seem to stimulate systemic 
inflammation in our study, a recent report demonstrated increased local inflammation up to 4 
hrs after an open AT biopsy 131 why this step of precaution may have been justified after all.
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In summary, vaccination activated systemic inflammation with increased TNF-α gene 
expression in PBMCs but did not trigger proinflammatory gene expression in AT. Also, we 
found a higher basal gene expression level of IL-6 in AT than in PBMCs. Further in vivo 
studies including a stronger stimulus to inflammation are needed to elucidate the inflammatory 
capacity of AT.
Paper II
Since vaccination was too weak to provoke AT inflammation we examined patients that were 
planned for open heart surgery with CPB, which is a stronger in vivo model of induced acute 
inflammation in humans, to further elucidate the inflammatory capacity of AT.
Acute systemic inflammation
Basic characteristics of subjects are described in detail in Table 1, paper II.  After approximately 
30-40 min of surgery and before institution of CPB, blood samples and the first biopsies from 
omental and subcutaneous AT were collected. At the end of surgery, when the patient had 
been weaned off CPB, a second sampling of blood and AT biopsies was collected.
Open heart surgery with CPB induced a 25-30 fold increase in plasma IL-6 levels 3.0 pg/ml 
(1.9-5.9) before and 79.8 pg/ml (31.5-190.8) after CPB, Figure 9a. 
Gene expression of proinflammatory markers in omental and subcutaneous adipose tissue
Relative quantification of adipose tissue mRNA gene expression after open heart surgery 
was calculated in relation to the house keeping gene cyclophylin A with the first biopsy 
in every paired sample as a reference, and expressed as change from baseline. IL-6, IL-8/
CXCL8 and E-selectin showed a 100-fold increase in mRNA expression in omental AT and 
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Figure 9. (a) Plasma levels of IL-6 before and after open heart surgery (p=0.008, n=14). 
(b) IL-6 levels in microdialysate from subcutaneous AT during and after open heart sur-
gery focused on the time period from 90 to 180 min after catheter insertion with both 
catheters in parallel. Dialysate from the 1st microdialysis catheter (MD1, n=4) showed in-
creased production of IL-6 ~ 3 hrs after start of surgery, and the 2nd microdialysis catheter 
(MD2, n=3), inserted 2.5 h after MD1 demonstrated increased IL-6 production already 
after 90 min with 2.3x higher mean levels of IL-6 vs. MD1 (p=0.005). 
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in subcutaneous AT these genes increased even more, up to 200-400-fold. The pattern of 
increased proinflammatory chemokine and cytokine gene expression was similar in omental 
and subcutaneous AT, Figure 10a-b.
The mRNA expression of receptors and transcription factors in omental and subcutaneous AT 
are presented in Figure 10c-d. In omental AT there was increased mRNA expression of IL-
1R1, NF-κB1, TLR2, TLR4 and TNFR-SF1A. A similar pattern was found in subcutaneous 
AT with increased mRNA expression of FOS, JUN, TLR2 and TNFR-SF1B.
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Figure 10. Relative adipose tissue mRNA gene expression after open heart surgery ex-
pressed as change from baseline.
Relative quantification (RQ) of mRNA gene expression of chemokines and cytokines (a 
and b) and receptors and transcription factors (c and d). RQ levels expressed in relation to 
the house keeping gene Cyclophylin A, using the first biopsy in every paired analysis as a 
reference and a logarithmic scale. Omental adipose tissue (7 patients) and subcutaneous 
adipose tissue (8 patients). * p<0.05, † p<0.02
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Gene expression findings verified by immunohistochemistry staining
To verify the increased mRNA expression on a protein level, staining and localization of 
active NF-κB-p65 was investigated by immunohistochemistry in AT biopsies. There was 
a marked staining of NF-κB-p65 in subcutaneous AT following surgery. NF-κB-p65 was 
localized to adipocyte nuclei, the endothelium and macrophages as illustrated in Figure 11 
a-b. Moreover, E-selectin stained strongly in the vascular endothelium after surgery, Figure 
11 c-d. Finally, we found a high number of macrophages in close contact with and in the 
vascular wall, Figure 11 e-f. Immunohistochemistry staining of omental AT biopsies showed 
a similar result as for subcutaneous biopsies but with less intensity.
IL-6 in microdialysate from subcutaneous adipose tissue
Local production of IL-6 in subcutaneous AT was analysed using microdialysis during and 
after open heart surgery. In total, IL-6 was measured in 7 microdialysis catheters; Dialysate 
was collected every 30 min and IL-6 increased in the dialysate from 14 (5-25) pg/ml, at 90 
min to a level of 147 (49-358) pg/ml, at 5 hrs (p<0.05). To avoid artefacts and to discriminate 
between local inflammation and secondary activation of AT inflammation by surgery, we 
used a second catheter membrane inserted at the end of surgery, two and a half hrs after the 
NFκB-P65
(a) (b)
(c) (d)
(e) (f)
NFκB-P65
E-Selectin E-Selectin
CD68 CD68
Figure 11. Representative micrographs of serial sections of subcutaneous adipose tissue 
before and after open heart surgery with cardiopulmonary bypass (CPB) demonstrating 
a marked upregulation of NF-κB-p65 (a and b) and a strong staining of E-selectin in the 
vascular endothelium (c and d) after CPB. There were also a high number of CD68 posi-
tive cells in close contact with the vascular endothelium migrating into the vessel wall (e 
and f). Arrows mark areas with strong positive staining.
Before CPB After CPB
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first membrane, assuming that local catheter-induced inflammation would result in similar 
IL-6 dynamics in both catheters. In dialysate from the first microdialysis catheter (n=4) there 
was an increased production of IL-6 approximately 3 hrs after start of surgery whereas in 
dialysate from the second microdialysis catheter, inserted 2.5 hrs after the first catheter, an 
increased IL-6 production was detected already 90 min after insertion (n=3). The mean levels 
of IL-6 in the second catheter were 2.3 times higher than the levels in the first catheter, Figure 
9b. During this period the lactate levels in dialysate were stable and did not increase in any 
of the patients. The lack of changes in lactate levels confirms a robust and well functioning 
microdialysis system.
Discussion
Although several studies have demonstrated an inflammatory capacity of AT 37, 41, 44-46, 50-54, 124, 
130, 132-135, the mechanism that triggers AT inflammation is still unknown. The present study not 
only confirms the results of these studies but also extends the knowledge about AT inflammatory 
capacity, by adding data from omental AT. Furthermore, whereas previous studies lack 
information about stimulated AT inflammation on a cellular level, our immunohistochemistry 
results clearly demonstrated that macrophages and vascular endothelium (E-selectin) of 
AT blood vessels became activated by open heart surgery. In addition, our findings from 
the microdialysis experiment confirm the results from the gene expression experiment and 
may indicate that the NF-κB-regulatory pathway is the key through which IL-6 synthesis in 
adipocytes is regulated. However, a contribution of IL-6 from macrophages and endothelium 
in AT blood vessels cannot be excluded. The AT IL-6 content after operative trauma has 
earlier been found to correlate with circulating levels of IL-6 132 but in our study, we found 
increased gene expression followed by IL-6 production in subcutaneous AT, measured by 
microdialysis, making it less likely that IL-6 in AT merely reflects plasma levels.
The results of the present study are consistent with earlier studies that demonstrated an 
extensive acute systemic inflammation with high plasma levels of both IL-6 and TNF following 
open heart surgery 111, 136. The acute phase response following CPB has been associated to 
increased gene expression of inflammatory mediators in circulating leukocytes, possibly due 
to contact of circulating blood with the synthetic surface of the CPB system 113, 114.
We speculated that circulating TNF activates the vascular endothelium and the surrounding 
AT to produce E-selectin and other inflammatory mediators through the NF-κB signalling 
pathway. Secondary to the expression of E-selectin and adhesion molecules on the vascular 
endothelium, circulating monocytes are recruited and activated to differentiate into 
macrophages with the possibility to extravasate into the surrounding AT. This could be one 
explanation for the recruitment of macrophages to AT resulting in the low-grade chronic 
inflammation seen in obese subjects 47. Another explanation for recruitment of macrophages 
into AT in obese individuals is increased levels of free fatty acids that can induce NF-κB 
activation by TLR4 followed by expression of cytokines, some of which suppress insulin 
signalling 13. However, the mechanisms for triggering AT inflammation could differ in low-
grade chronic and acute systemic inflammatory conditions.
It is well documented that the injury inflicted by surgery evokes increased release of cytokines 
and stress hormones 137. However, these are not solely produced in AT, other sources 
such as skeletal muscle have also been demonstrated with increased mRNA expression 
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of proinflammatory markers after surgery 138. A central effect of these mediators is the 
development of insulin resistance 137, supported in previous studies which have reported on 
an improved glucose tolerance after neutralization of TNF in obese rodents 139, 140.
Our results give further support to an AT inflammatory capacity in contribution to the acute 
systemic inflammation and thereby possibly aggravating the increased insulin resistance 
seen during surgery 137. In these studies, this effect was transient and therefore may be of 
minor long-term clinical relevance, but if AT recruitment of macrophages during the acute 
phase of inflammation also contributes to the low-grade chronic AT inflammation seen in 
obese individuals, it may have a deeper impact on metabolic disorders and long-term clinical 
relevance. Indeed, we found a positive correlation between the need for insulin during the 
first 24 hrs after start of surgery and relative quantification of IL-1β gene expression (R=0.86, 
p=0.014) and non-significant positive trends between the need for insulin and relative 
quantification of CCL-2 and IL-6 gene expression in omental AT after surgery. However, due 
to the low number of study subjects it is impossible to draw any definitive conclusion from 
the correlation analyses. The need for insulin together with activation of AT inflammation 
could be investigated in a future study of the role of obesity during surgery.
In summary, systemic inflammation stimulates AT to produce an innate inflammatory 
response due to upregulation of the NF-κB regulatory pathway. First, gene expression of 
several proinflammatory genes increased dramatically after open heart surgery with a similar 
pattern in both omental and subcutaneous AT. Second, the increased gene expression was 
confirmed by immunohistochemistry showing strong expression of E-selectin with a high 
number of macrophages in close contact with and in the vascular wall. Third, increased 
gene expression of inflammatory mediators was followed by increased production of IL-6 
in subcutaneous adipose tissue measured by microdialysis. It can be hypothesized that AT 
exerts a modulatory effect on innate immunity in humans and that the inflammatory response 
aggravates insulin resistance.
Paper III
CVD events such as myocardial infarctions are known complications after surgery and severe 
infection where acute systemic inflammation is a common denominator. In the light of our 
previous findings on AT inflammation we proceeded with studies on plasminogen activator 
inhibitor-1 (PAI-1) synthesis in AT after acute systemic inflammation, in order to investigate 
a possible mechanism behind these complications.
Plasma levels of IL-6 and PAI-1 during and after open heart surgery
To investigate circulating concentrations of IL-6 and PAI-1 antigen, blood samples were 
collected before and after open heart surgery with a median time of 125 (90-285) min between 
the paired samples. We confirmed our findings from paper II, with the observation of  a more 
than 25-fold increase in plasma IL-6 levels, in median 3.1 pg/ml (3.0-5.9) before and 85.2 
pg/ml (31.5-218.2) after surgery.
No significant differences were found in plasma levels of PAI-1 antigen analyzed before and 
after CPB (Figure 3a Paper III). In subjects further investigated with plasma samples every 
hour up to 6 hrs after start of surgery, a positive linear trend was found in plasma levels of 
PAI-1 antigen with an increase after 4 hrs after start of surgery (Figure 3b Paper III).
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PAI-1 gene expression in adipose tissue
There was an increased mRNA expression of PAI-1 in both omental and subcutaneous AT 
after open heart surgery, Figure 12. When these results are expressed as relative quantification 
using the first biopsy in every paired sample as a reference, the gene expression of PAI-1 
in omental AT showed a 27-fold increase after surgery whereas a 3-fold increased gene 
expression was found in subcutaneous AT. The degree of PAI-1 mRNA increase was higher 
in omental compared to subcutaneous AT. No difference was found in basal PAI-1 gene 
expression between the two AT depots.
Staining for PAI-1 protein in adipose tissue
To confirm production of PAI-1 at a protein level and to investigate the localization of 
PAI-1 in AT, we stained for PAI-1 antigen in subcutaneous AT biopsies. There was a marked 
increased staining of PAI-1 antigen detected within the vascular endothelium as well as in the 
adventitia of AT vessels after open heart surgery. PAI-1 antigen was also detected in the AT 
interstitium close to AT vessels and in solitary cells in between adipocytes, Figure 13.
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Figure 12. Relative quantification of plasminogen activator inhibitor-1 (PAI-1) gene ex-
pression in omental and subcutaneous adipose tissue (AT) before and after open heart 
surgery with cardiopulmonary bypass (CPB). Gene expression of PAI-1 expressed in rela-
tion to the house keeping gene cyclophylin A. No difference was found in basal levels of 
PAI-1 gene expression between the two different AT depots. After open heart surgery 
there was increased mRNA expression of PAI-1 in both omental (p=0.028, n=7) and sub-
cutaneous AT (p=0.002, n=12). Median time between samples was 125 (90-285) min.
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Figure 13. Localization of plasminogen activator inhibitor-1 (PAI-1) antigen in subcutaneous 
and omental adipose tissue (AT) before and after open heart surgery.
Representative immunohistochemical analyses of paraffin sections showing vasculature 
and adipocytes in subcutaneous (a) (n=5) and omental (b) (n=1) AT before and after cardio-
pulmonary bypass (CPB). Strong staining of PAI-1 was detected within the endothelial cells 
as well as in the adventitia, after surgery. PAI-1 antigen was also detected in the AT intersti-
tium close to AT vessels and in solitary cell nuclei in between adipocytes.
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Discussion
Our results, with a markedly higher PAI-1 gene expression in omental compared to subcutaneous 
AT following surgery, underlines the importance of abdominal fat distribution in obesity. An 
intensified synthesis of PAI-1 in human AT following stimulation could severely impair the 
fibrinolytic activity in plasma and may therefore explain the risk of myocardial infarction seen 
after surgery or infection. The PAI-1 response in omental AT following stimulation could also be 
one of the explanations why obesity is an independent risk factor for myocardial infarction 12.
Our gene expression results confirm earlier ex vivo studies where higher PAI-1 synthesis in omental 
versus subcutaneous cultured adipocytes following stimulation was demonstrated 91, 141. Another 
study showed a lower ex vivo secretion rate of PAI-1 in omental compared to subcutaneous 
AT 142, however, this study investigated PAI-1 production in non-stimulated conditions. Other 
studies have not been able to demonstrate any differences between the two different AT depots. 
Basal arterio-venous concentrations of PAI-1 antigen across omental and subcutaneous AT were 
measured, but neither of them could show any significant differences across different AT beds 
in vivo 81, 143. Nevertheless, the contribution of different AT beds to circulating PAI-1 could differ 
in health and disease. A greater arterio-venous difference in PAI-1 activity in diabetic compared 
to non-diabetic subjects has been reported, but the groups were small and the results were not 
paralleled by PAI-1 antigen concentrations.
Ex vivo experiments have shown that angiotensin II stimulates PAI-1 gene expression in human 
adipocytes, a stimulation which was completely blocked by angiotensin-converting enzyme 
inhibitors or angiotensin receptor blockers (ACEi/ARBs) 99. The use of angiotensin II inhibitors 
has also been reported to alter fibrinolytic activity during open heart surgery 144. In paper III, 
six out of twelve subjects were treated with ACEi/ARB medication, all with maximal doses. 
However, we could not find any differences in PAI-1 gene expression between patients with 
or without angiotensin II blocking medication. Hence, we conclude that angiotensin II is not a 
likely major stimulatory factor of PAI-1 synthesis in AT during acute systemic inflammation.
Notably, we found a markedly increased gene expression of PAI-1 and a strong staining of 
PAI-1 antigen in AT biopsies taken already when the patient had been weaned off CPB, while 
plasma levels of PAI-1 did not increase until hours after surgery. This clearly suggests that the 
PAI-1 protein detected in AT precedes the increase in plasma PAI-1 levels, a finding that could 
be highly relevant. It indicates that PAI-1 synthesis in AT significantly contributes to the later 
increase in plasma concentrations of PAI-1.
The results of the present study are of potential major clinical relevance. The increased risk of 
myocardial infarction seen after major surgery does not appear during the surgical procedure 
itself, characterized by the stress from anaesthesiology and surgical trauma, but occurs during 
the early postoperative period 18. The same phenomenon is found after a severe infection with 
the highest risk of myocardial infarction during the first week after onset of infection 19. Both 
surgery and infection result in an acute systemic inflammation and the delay in time indicates that 
putative risk factors for myocardial infarction are synthesized as a response to the acute phase 
reaction. Support for this hypothesis is that chronically elevated levels of PAI-1 are associated 
with spontaneous coronary arterial thrombosis in transgenic mice 84 and that increased activity 
of PAI-1 on the first day after CABG correlates to early vein graft occlusion 145. Other systems 
important for coagulation and haemostasis may also react upon an acute systemic inflammation; 
increased plasma levels of activated factor VII following an acute inflammation 103 and platelet 
activation after bacterial infection 87, 146.
The merged results from Paper II and Paper III indicate that PAI-1 synthesis in AT is regulated 
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through the NF-κB signalling pathway, congruent with a recent review by Kruithof 147 and supported 
by previous findings from animal studies 94 and ex vivo experiments on human adipocytes 91 where 
LPS or TNF were used as inflammatory stimuli.
In summary, - PAI-1 gene expression and protein synthesis in AT was induced after acute systemic 
inflammation. The increase was most prominent in omental AT. PAI-1 produced by AT preceded 
the increase in plasma levels of PAI-1 and may be a link between inflammation and impaired 
fibrinolytic activity causing myocardial infarction.
Paper IV
Regulation of adipokines in the early phase of an acute inflammation in humans is of considerate 
interest as they are suggested to have an important role also in chronic inflammation and in the 
development of atherosclerosis. However, the control mechanisms of adiponectin and leptin 
during an acute inflammatory response are still poorly understood. Paper IV is a sub-study to the 
studies in paper I and II where acute inflammation was induced by vaccination and open heart 
surgery respectively, with the aim to investigate the effects on adiponectin and leptin synthesis.
Plasma levels of adipokines and IL-6
Plasma levels of adiponectin and leptin were unaltered after vaccination, showing similar levels 
as in the control group (Figure 1, paper IV) although the plasma levels of IL-6 increased 3-4-fold 
with a significant difference at 8 hours after vaccination.
Gene expression of adipokines
As open heart surgery with CPB is a strong inducer of systemic inflammation, we analyzed 
relative mRNA gene expression for adiponectin and leptin after open heart surgery, expressed 
as change from baseline in both omental and subcutaneous AT biopsies. Neither adiponectin nor 
leptin mRNA from omental AT did change after open heart surgery with a median time of 125 (90-
285) min between the biopsies. Similar results were obtained for subcutaneous AT, Figure 14.
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Figure 14. Relative AT mRNA gene expression of adiponectin and leptin (a) in omental AT and 
(b) subcutaneous AT after open heart surgery, expressed as change from baseline.
Relative quantification expressed in relation to the house keeping gene cyclophylin A, using 
the first biopsy in every paired analysis as a reference and a logarithmic scale. Omental AT 
(n=7) and subcutaneous AT (n=8).
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Discussion
Recent studies regarding circulating concentrations of adiponectin and leptin during acute 
systemic inflammation has demonstrated a reduction of adiponectin, inversely correlated 
to C-reactive protein with a decrease 24 hrs after myocardial infarction 148. Furthermore, 
leptin increase in plasma following open heart surgery, but not until 24 hrs post-surgery 149. 
There are also some recent in vivo studies that have focused on both adiponectin and leptin 
synthesis in relation to acute inflammation, where leptin levels increased in plasma after LPS 
injection but adiponectin levels remained unchanged 52.
However, in our study we did not find any differences in plasma levels of adiponectin or 
leptin up to 24 hrs after vaccination. One explanation is that our vaccination model was too 
weak to induce a potent systemic inflammation, something which is supported by the very 
modest increase in IL-6 plasma levels (Paper I). Despite a strong systemic inflammation 
induced by open heart surgery, there was still a lack of changes on a gene expression level of 
adiponectin and leptin.
Possible reasons for this could be that that we have analyzed the AT gene expression too 
early or that these adipokines are not key elements in the acute-phase response. However, our 
results do not exclude that adiponectin and leptin levels change later during the inflammatory 
response.
Recent in vivo studies have focused on both adiponectin and leptin gene expression in relation to 
acute inflammation. Anderson and co-workers showed that LPS suppressed adiponectin gene 
expression in subcutaneous AT, whereas there was a trend towards increased gene expression 
of leptin 52. Jernås and co-workers found no effect of inflammation, caused by subarachnoidal 
haemorrhage, on adiponectin and leptin mRNA gene expression in subcutaneous AT 150. The 
reason for these somewhat discrepant results is not clear, but methodological issues have to 
be considered. First, the stimulus to systemic inflammation was different between the studies. 
Anderson et al 52 used LPS whereas we (in the open heart surgery study group) and Jernås 
et al 150 used tissue damage. These are strong inducers of systemic inflammation but might 
activate different subsets of cells, including macrophages in AT. Also the time-frames were 
different.
One limitation in our study may be the low number of patients investigated in the gene 
expression experiment. However, we used paired AT biopsies, which minimize a possible 
inter-individual variation. Furthermore, the size of the study group was large enough to 
demonstrate a very rapid onset of a marked innate immune response in AT following systemic 
inflammation induced by open heart surgery 112.
Both models of stimulated systemic inflammation used in this study activate inflammation 
through the nuclear factor-κB regulatory pathway 105, 112 and interestingly, none of the models 
were shown to have any influence on the synthesis of adiponectin or leptin. This suggests 
that the nuclear factor-κB signalling pathway is not involved in the regulation of these two 
adipokines in an acute-phase response. This is also supported by a recent study by Diez and 
co-workers who showed that leptin was not found to act as an acute phase reactant but more 
as a marker of nutritional status in patients with pneumonia 151.
When leptin synthesis has been studied in cultured human subcutaneous adipocytes it has 
been demonstrated that TNF attenuated leptin mRNA gene expression but in contrast, induced 
an increased protein release 152. Furthermore, the proinflammatory cytokines IL-1β and TNF 
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both decreased leptin gene expression and protein production in vitro, but still IL-1β was 
found to elicit an early release of leptin to circulating plasma 153. Interestingly, the results of 
these two in vitro studies suggest a pre-formed pool of leptin in human AT with a paracrine 
regulation to which IL-1β and TNF could be important key regulators. However, this pool 
has not yet been identified and it is not clear whether human adipocytes stimulated in vitro 
adequately represent the situation on a tissue level in vivo.
In summary, despite the use of two models of induced in vivo systemic inflammation we 
found no evidence of an early regulation of adiponectin and leptin synthesis, indicating that 
these two adipokines are not key elements in an acute systemic inflammation in humans. Our 
results extend previous studies by also analyzing gene expression in omental AT.
Concluding remarks and future perspectives
This thesis presents the novel finding that an acute systemic inflammation, stimulated by open 
heart surgery, induces a strong inflammatory response in both omental and subcutaneous AT 
including adhesion of macrophages to activated endothelium and release of IL-6 from AT 
interstitium. Moreover, the AT inflammation results in increased AT synthesis of PAI-1, an 
increase which is most prominent in omental compared to subcutaneous AT, and followed by 
a later increase in plasma levels. Our results are both new and of clinical relevance. As always, 
new findings lead to new questions. Several research areas focusing on acute inflammation 
need to be further elucidated.
The human innate immune system has developed during evolution as an acute-phase 
response to local or systemic infections. As AT has been demonstrated to be an organ capable 
of producing several proinflammatory active components, it may potentiate the acute phase 
response thus serving as a survival benefit, beyond the advantage of being an energy depot.
However, the possible benefits of AT most likely become disadvantageous with increasing 
overweight and/or obesity, as this is intimately associated with obesity-induced insulin 
resistance and diabetes mellitus predisposing to atherosclerosis and subsequent CVD 10. This 
is also supported by animal studies 154. However, recent studies have reported on an “obesity 
paradox” where obese subjects seem to have increased risk of morbidity but not mortality 
compared with lean or underweight subjects but this remains to be further investigated 155-
158.
When we interpret results from studies on AT inflammation and its clinical implications, we 
have to underline the importance of differentiate a low-grade chronic inflammation from an 
acute systemic inflammation. As current knowledge regarding AT inflammatory capacity, to a 
great extent relies on experiments and studies done in non-stimulated or chronic inflammatory 
conditions, it is important to add these data from human studies, using different models of 
induced acute systemic inflammation.
Our findings regarding the correlation between increased IL-1β gene expression in omental 
AT and the need for insulin to keep normal glucose levels during surgery indicate that AT 
inflammation contributes to insulin resistance during surgery. Further, we found positive 
tendencies between the need for insulin and increased gene expression of the inflammatory 
associated molecules CCL-2 and IL-6 in omental AT after surgery. The importance of 
inflammation in the development of insulin resistance is supported by a recent study 
Mattias Ekström
42
demonstrating that non-insulin resistant obese individuals lack the inflammatory response that 
characterizes the insulin resistant obese individuals 159. Unfortunately, the limited number of 
patients also being only men, make it impossible to do any definitive conclusions regarding 
insulin resistance and AT inflammatory response.
Probably, all obese individuals are at risk of developing insulin resistance why it would be 
of interest to measure circulating levels of IL-6 and the need for insulin together with AT 
inflammation during the peri-operative as well as the post-operative period in a substantial 
number of female and male patients, to further investigate if the inflammatory response to 
open heart surgery is stronger in overweight patients due to secondary activation of AT. 
Another way to test this hypothesis would be the use of a single dose of LPS as a model of 
induced systemic inflammation.
We used microdialysis to investigate proteins on a tissue level and confirm the gene expression 
results but only IL-6 levels were analyzed. In a future project it would be appealing to collect 
dialysate for a longer period, even days. We used ELISA to analyze the dialysate but there 
are other techniques, such as multi-plex systems that enable analysis of a great number of 
different cytokines and chemokines in small sample volumes.
Today, we do not know if obese individuals have a stronger inflammatory response due to 
their high percent body fat, compared to normal-weight or lean individuals. This need to 
be further investigated. In addition, inter-individual differences in the acute phase response 
could also be explained by different genotypes. In the vaccination study group we tried to 
control for differences in inflammatory response due to genotype by including only subjects 
homozygous for the common -174 G allele in the -174 G>C polymorphism which has been 
shown to be associated with increased plasma levels of IL-6 after vaccination 126. However, 
in the open heart surgery study group, it was not possible to take IL-6 genotype differences 
into consideration. Instead we collected and analyzed paired tissue and blood samples which 
minimize the influence of inter-individual variability, thereby indirectly controlling for other 
genetic variations as well.
Another interesting clinical aspect is that body mass index is a risk factor for post-operative 
atrial fibrillation, and lipid-lowering therapy with statins may reduce this risk due to the anti-
inflammatory properties of these drugs. Our data regarding the role of AT in the inflammatory 
response to open heart surgery could result in treatment alternatives in patients with overweight 
by considering statins for all patients in this category 160, 161.
Beyond diabetes mellitus, hypertension, and hyperlipidaemia, the close association between 
elevated plasma levels of PAI-1 and abdominal fat distribution has led to the inclusion of 
impaired fibrinolysis in an expanded definition of the metabolic syndrome 86, 93, 162. Numerous 
studies have demonstrated that patients with the metabolic syndrome are at high risk for 
developing cardiovascular disease, venous thrombosis and pulmonary embolism 10, 163, 164. 
Increased PAI-1 activity predict cardiovascular events in patients with a history of an earlier 
myocardial infarction 83 and elevated PAI-I levels are associated to spontaneous coronary 
artery thrombosis in mice 84. In this thesis we showed that an acute systemic inflammation 
in humans activated AT inflammation through the NF-κB signalling pathway together 
with an increased gene expression and protein synthesis of PAI-1. Noteworthy, we found 
a similar pattern regarding genes encoding pro-inflammatory effects in both omental and 
subcutaneous AT and maybe, it is time to start considering AT as an organ/tissue of innate 
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immunity. Moreover, our results indicate that during inflammation and/or infection, it is the 
abdominal fat that plays the most important role for the synthesis of PAI-1 as well as for the 
development of insulin resistance. However, other sources of increased PAI-1 synthesis, such 
as activated endothelium and/or platelets also need further investigation.
PAI-1 synthesis in AT due to acute systemic inflammation may be the link between 
inflammation and impaired fibrinolytic activity that might explain the increased risk of acute 
myocardial infarction seen after surgery or infection. A PAI-1 inhibiting antibody could be a 
new therapeutic strategy trying to reduce this risk.
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CONCLUSIONS
I. Vaccination activates systemic inflammation but does not trigger proinflammatory 
gene expression in AT.
II. Acute systemic inflammation induced a strong inflammatory response in both omental 
and subcutaneous AT, including adhesion of macrophages to an activated endothelium 
and release of IL-6 from AT interstitium.
Acute systemic inflammation increased gene expression and protein synthesis of  PAI-III. 
1 in human AT and that this increase was more prominent in omental compared to 
subcutaneous AT.
Despite the use of two models of stimulated systemic inflammation we found no IV. 
evidence of an early regulation of adiponectin and leptin synthesis, indicating that 
these adipokines are not key elements in an acute systemic inflammation in humans.
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Vaccination, a human model of inflammation, activates
systemic inflammation but does not trigger
proinflammatory gene expression in adipose tissue
Dear Sir,
Inﬂammation plays a key role in the development of
atherosclerosis [1]. Many studies have emphasized
inﬂammatory markers as prognostic for atherosclerosis
and myocardial infarction [2, 3]. One of these, inter-
leukin-6 (IL-6), is a multifunctional cytokine with an
important role in host defence. It is involved in the
development of cells and tissues as well as in differ-
ent pathological conditions. IL-6 is not constitutively
produced but can be synthesized in response to
inﬂammatory stimuli such as interleukin-1b (IL-1b),
lipopolysaccharide and tumour necrosis factor-alpha
(TNF-a) [4, 5]. IL-6 is produced by many different
cell types including monocytes ⁄macrophages, ﬁbro-
blasts, endothelial cells and adipocytes. It regulates
production of adhesion molecules involved in the
release of other cytokines and induces the hepatic
synthesis of C-reactive protein (CRP). In vivo release
of IL-6 from human adipose tissue (AT) has been
demonstrated [6]. Furthermore, positive associations
between IL-6 and TNF-a in AT and circulating CRP
have been shown [7]. TNF-a is synthesized by cells
of the immune system and it is a strong mediator of
inﬂammatory and immune functions [5]. Furthermore,
it is known to regulate growth and differentiation of
many different cell types. Macrophages in AT can
produce TNF-a shown to be associated with proin-
ﬂammatory activity that may contribute to atheroscle-
rosis [8]. IL-1b is produced by several cell types
including macrophages and it is a potent inducer of
fever and the acute phase response [5]. The positive
correlation seen between proinﬂammatory cytokines
in AT and circulating CRP is of particular interest as
it has been shown that decreased AT macrophage
inﬁltration was associated with an improved inﬂam-
matory proﬁle following weight loss in obese subjects
[9]. Moreover, a positive association between body
mass index and death from cardiovascular disease has
been demonstrated [10], indicating that AT proinﬂam-
matory cytokines are pathogenic in atherosclerosis.
To elucidate a possible connection between systemic
inﬂammation and inﬂammatory activity in AT in
humans, we investigated whether a standardized
inﬂammatory stimulus activates AT and circulating
peripheral blood mononuclear cells (PBMC). To stan-
dardize inﬂammation, we used a model of vaccination
against Salmonella typhi. Current knowledge about
stimulated inﬂammatory activity in different cell types
and tissues is mostly based on animal and in vitro
studies, therefore it is of particular interest to investi-
gate this in humans. Our hypothesis was that an acute
systemic inﬂammation would stimulate inﬂammatory
activity in AT that could sustain the systemic inﬂam-
matory response.
Eighteen healthy volunteers (16 men and two post-
menopausal women) who had participated in two pre-
vious studies were invited (Table 1). Every second
individual was allocated to the vaccine or control
group. There have been conﬂicting data as to whether
genetic variation in the IL-6 gene could explain vari-
ability in stimulated plasma levels of IL-6 [11–13].
Results from our group have clearly demonstrated that
the G-allele of the 174 G>C polymorphism in the
promoter region of the IL-6 gene is associated with
increased IL-6 levels in plasma after vaccination [14].
To avoid differences in inﬂammatory response due to
this polymorphism all subjects in this study were
homozygous for the common )174 G allele. All sub-
jects gave informed written consent for participation
in the study which was approved by the Ethics
Committee of the Karolinska Institutet.
Venous blood samples were obtained after 0, 4, 8,
12 and 24 h. After the initial blood sample, subjects
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in the vaccine group received an injection with vac-
cine against S. typhi (Typhim Vi; Sanoﬁ Pasteur
MSD, Solna, Sweden), 0.5 mL (25 lg), intramuscu-
larly in the left shoulder. Four hours after the ﬁrst
blood sampling all subjects underwent a subcutane-
ous fat biopsy from the periumbilical area of the
abdomen, as described previously[15]. The biopsy of
300–500 mg was washed in saline and immediately
frozen in RNAlater (Ambion, Inc., Austin, TX,
USA) at )70C for gene expression studies. At 0
and 4 h venous blood samples were obtained for
analysis of gene expression. These blood samples
were taken in cell preparation tubes (BD, Franklin
Lakes, NJ, USA) for separation of PBMC from
whole blood. IL-6 in EDTA plasma was analysed
by a high sensitivity enzyme immunoassay (R&D
Systems Inc., Minneapolis, MN, USA).
Total RNA was extracted from PBMCs using the
QIAamp RNA blood mini kit (Qiagen GmbH, Hilden,
Germany). RNA was extracted from fat biopsies using
the RNeasy mini kit (Qiagen). An Agilent 2100 Bio
analyzer (Agilent Technologies, Inc., Santa Clara, CA,
USA) was used to conﬁrm the quality of extracted
RNA. An ND-1000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA) was used to
analyse the concentration of RNA. Three hundred
nanograms of RNA from each sample was reverse
transcribed to complementary DNA (cDNA) using the
Invitrogen superscript ﬁrst strand synthesis system for
real time polymerase chain reaction (RT-PCR) using
the random primers (Invitrogen Corporation, Carlsbad,
CA, USA). To investigate which house keeping gene
to use, cDNA from PBMCs from four of the subjects
from the vaccine group were analysed before and 4 h
after vaccination using the TaqMan Human Endoge-
nous Control Plate as described (Applied Biosystems,
Foster City, CA, USA). Cyclophylin A was stable
during inﬂammatory stimulation and had a suitable
Ct-value. To analyse gene expression 3 lL of cDNA
was mixed with TaqMan universal PCR master mix
(2·) (Applied Biosystems; Branchburg, NJ, USA) and
primer-probe mix (20·) with Taqman gene expression
assays (Applied Biosystems) to a ﬁnal volume of
25 lL. The gene expression assays used for quantita-
tive RT-PCR (TaqMan) were cyclophylin A
(Hs99999904_m1), IL-1b (Hs00174097_m1), IL-6
(Hs00174131_m1) and TNF-a (Hs00174128_m1).
Table 1 Demographic data and
basic characteristics
Variable
Vaccine group
(n = 9)
Control group
(n = 9) P-value
Age, years 59 (58–64) 60 (59–63) NS
Sex (men ⁄women) 8 ⁄ 1 8 ⁄ 1 NS
Current smokers, n (%) 2 (22) 1 (11) NS
Body weight, kg 93 (75–100) 90 (81–94) NS
BMI, kg m)2 25 (24.5–27.2) 28.2 (25.6–29.1) NS
Waist circumference, cm 94.5 (84.3–103.5) 96 (91–100.5) NS
Blood pressure, mmHg
Systolic 140 (125–140) 140 (120–140) NS
Diastolic 90 (80–95) 80 (70–85) NS
Heart rate, bpm 64 (58–72) 60 (52–64) NS
Plasma glucose, mmol L)1 5.5 (5.2–5.7) 5.1 (4.9–5.7) NS
Plasma cholesterol, mmol L)1 5.0 (4.6–5.1) 5.9 (5.2–6.0) NS
Plasma LDL, mmol L)1 3.3 (3.2–3.5) 3.8 (3.1–4.5) NS
Plasma HDL, mmol L)1 1.1 (0.9–1.2) 1.3 (1.0–1.5) NS
Plasma triglycerides, mmol L)1 1.4 (1.0–1.5) 1.0 (0.9–2.7) NS
Data are presented as median (interquartile range) and n (%). BMI, body mass index; NS, not
signiﬁcant.
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Gene expression results for IL-1b, IL-6 and TNF-a
were calculated as an index in relation to the cyclo-
phylin A gene expression in each sample.
The results showed that in PBMCs, there was a sig-
niﬁcant increase in TNF-a mRNA gene expression
4 h after vaccination when compared with the control
group (P = 0.047). There were no differences in
mRNA gene expression of IL-1b and IL-6 between
the vaccinated group and controls (Fig. 1a). In AT
there were no differences in mRNA gene expression
of IL-1b, IL-6 or TNF-a between the vaccine and the
control group (Fig. 1b). The gene expression of IL-6
was higher in AT compared with PBMC (P = 0.003)
and the gene expression of IL-1b was higher in
PBMC compared with AT (P = 0.0002) taking the
vaccinated group and controls together.
Plasma levels of IL-6 were higher in the vaccine
group 8 h after vaccination, 4.86 ± 9.3 pg mL)1 com-
pared with 1.6 ± 2.0 pg mL)1 in the control group
(P = 0.02). (Fig. 2).
Previous studies on the inﬂammatory response after
vaccination have not been able to measure any
increase in plasma levels of TNF-a [14, 16]. The rea-
son for this is not clear but one can speculate that the
increased TNF-a expression in PBMCs seen in the
present study is due to activated monocytes ⁄macro-
phages released from the vaccinated tissue. The upreg-
ulation of TNF-a gene expression might not be
enough to result in detectable plasma levels of the pro-
tein but the increased plasma levels of IL-6 support
the experimental model of vaccination as a stimulus to
systemic inﬂammation. The lack of upregulation of
IL-6 gene expression in PBMCs 4 h after vaccination
is likely to be due to differentiation of monocytes to
macrophages of the subset of PBMCs with IL-6 gene
expression thereby being trapped at the site of inﬂam-
mation. According to our results TNF-a is a more rele-
vant stimulus than IL-1b in stimulating IL-6 thereby
extending previous studies in animals and in vitro [4].
One previous study has shown in vivo release of IL-6
from human subcutaneous AT [6]. However, the regu-
lation of this synthesis is largely unknown. Our results
support this study by demonstrating unstimulated IL-6
gene expression in AT. Interestingly, the basal level of
mRNA gene expression was fourfold higher in AT
compared with PBMCs. However, we were not able to
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Fig. 1 RNA expression of inﬂammatory cytokines in
relation to house keeping genes. (a) Peripheral blood
mononuclear cells (PBMC). (b) Adipose tissue. Indexes of
quantitative RNA gene expression of interleukin-1b (IL-1b),
interleukin-6 (IL-6) and tumour necrosis factor-a (TNF-a) in
relation to the house keeping gene cyclophylin A.
Vaccinated subjects in striped boxes and controls in open
boxes. Data are presented as median; box, 25–75%;
whisker, nonoutlier range.
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Fig. 2 Plasma levels of interleukin-6 (pg mL)1). Vaccinated
group in squares and controls in triangles. Data are
presented as mean + SEM.
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stimulate AT by vaccination. In contrast, Hoch et al.
demonstrated increased transcription of IL-6 mRNA in
human adipocytes stimulated ex vivo by lipopolysac-
charides [17]. The reason for this discrepancy might
be that we used a weaker stimulus to systemic inﬂam-
mation. Furthermore, Memoli et al. showed that
patients with chronic inﬂammation had increased IL-6
expression in AT when compared with patients with
normal levels of inﬂammatory markers [18], suggest-
ing that AT might respond to stimulation. Further
in vivo studies with stronger stimulus to inﬂammation
are needed to resolve this issue.
Plasma levels of IL-6 in our study increased only four-
fold compared with basal values. Previous results from
our group have shown that plasma IL-6 levels increased
10-fold after vaccination [14]. Compared with this
study, subjects did not have an indwelling peripheral
vein catheter during the study, otherwise the protocol
was similar. The absence of an indwelling catheter
could probably explain the difference in peak plasma
IL-6 levels. To avoid the risk that a haematoma caused
by the fat biopsy would stimulate systemic inﬂamma-
tion, we compared vaccinated subjects with nonvacci-
nated subjects instead of using subjects as their own
controls. Interestingly, the biopsy did not seem to stim-
ulate systemic inﬂammation. One limitation of the pres-
ent study is that fat biopsy was taken only once, at 4 h.
The reason for the time chosen for fat biopsy was that
we have shown that circulating IL-6 starts to increase
4 h after vaccination [14]. We cannot exclude that fat
biopsy at other time-points would have resulted in a
different result.
In conclusion, we have shown that vaccination, a
human model of inﬂammation, which causes endothe-
lial dysfunction and activates coagulation [16, 19],
stimulates a mild systemic inﬂammation but does not
trigger proinﬂammatory gene expression in AT. Fur-
ther in vivo studies including a stronger stimulus to
inﬂammation are needed to elucidate the inﬂammatory
capacity of AT.
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Previous studies lack information about stimulated AT in-
flammation on a cellular level. Our results showed that several
cell types within AT became activated by open heart surgery;
immunohistochemistry showed activation of macrophages and
endothelium (E-selectin) of AT blood vessels, whereas micro-
dialysis from AT interstitium demonstrated increased IL-6
synthesis, to which, e.g., activated adipocytes, preadipocytes,
and macrophages, could have contributed.
Microdialysis is a validated method to gain access to and
sample adipose-derived molecules from the intercellular space,
providing valuable information at a tissue level (5, 20, 27).
These studies have indicated a risk of an artifact due to trauma
from the catheter. Possibly, this risk may depend on which
insertion technique and catheter membrane were used. To
avoid this artifact risk, we used a two-catheter membrane
protocol where the second membrane was inserted 2.5 h after
the first membrane, assuming that local catheter-induced in-
flammation would result in similar IL-6 dynamics in both
catheters. Our results showed an increased IL-6 production
detected in dialysate from the first microdialysis catheter 3 h
after catheter insertion, but we can clearly demonstrate an
increased IL-6 production in the second microdialysis catheter
already at 90 min. This result confirms the findings from the
gene expression experiment, and the NF-B regulatory path-
way might be the key through which IL-6 synthesis in adipo-
cytes is regulated. However, a contribution of IL-6 from
macrophages and endothelium in AT blood vessels cannot be
excluded.
Open heart surgery results in an extensive acute systemic
inflammation with high plasma levels of both IL-6 and TNF
(2). This has previously been shown to be a result of gene
expression of inflammatory mediators in circulating leukocytes
(6, 21). Other sources of inflammatory mediators have not been
investigated previously. One may speculate that circulating
TNF activates the vascular endothelium and the surrounding
AT to produce E-selectin and other inflammatory mediators
through the NF-B regulatory pathway. Secondary to the
expression of E-selectin and adhesion molecules on the vascu-
lar endothelium, circulating monocytes are recruited and acti-
vated to differentiate into macrophages with the possibility to
Fig. 2. Immunohistochemistry staining of subcuta-
neous AT. Representative micrographs of serial sec-
tions of subcutaneous AT before and after open
heart surgery with cardiopulmonary bypass (CPB)
demonstrating a marked upregulation of NF-B-p65
(A and B) and a strong staining of E-selectin in the
vascular endothelium (C and D) after CPB. There
were also a high number of CD68-positive cells in
close contact with the vascular endothelium migrat-
ing into the vessel wall (E and F). Arrows mark
areas with strong positive staining.
Table 3. Results from immunohistochemistry
Before CPB After CPB
Group 0 
 

 


 0 
 

 



E-selectin 0 5 0 0 0 0 2 3
NF-B-p65 0 3 2 0 0 0 0 5
CD68 0 5 0 0 0 0 2 3
Table demonstrates evaluation results of immunohistochemical staining of
subcutaneous adipose tissue sections from 5 subjects. A semiquantitative scale
from 0 to 


 (0 	 no positive cells, 
 	 25% positive cells, 

 	
25–75% positive cells, 


 	 75% positive cells) was used for evaluation
of staining of E-selectin, NF-B-p65. and CD68.
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Abstract
Objective
Cardiovascular events are known complications after surgery and severe infection where 
acute systemic inflammation is a common denominator. To investigate a possible mechanism 
behind these complications we have studied plasminogen activator inhibitor-1 (PAI-1) 
synthesis in adipose tissue (AT) after acute systemic inflammation, induced by open heart 
surgery.
Methods
Twenty-two patients underwent blood sampling and omental and subcutaneous AT biopsies 
for gene expression studies before and after surgery. Expression and localization of PAI-1 in 
AT was evaluated by immunohistochemistry.
Results
After surgery, gene expression of PAI-1 increased 27-fold in omental AT and 3-fold in 
subcutaneous AT. PAI-1 antigen was localized within endothelial cells, in the AT interstitium 
close to AT vessels and in solitary cells between the adipocytes. The upregulated gene 
expression and protein synthesis in AT was followed by increased concentrations of PAI-1 
antigen in plasma.
Conclusions
For the first time in vivo, we present that an acute systemic inflammation increased gene 
expression and protein synthesis of PAI-1 in human AT. The increase was most prominent 
in omental AT. PAI-1 synthesis in AT, following acute inflammation, may be a link between 
inflammation and impaired fibrinolytic activity that might explain the risk for myocardial 
infarction after surgery or infection.
Ekström et al
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Introduction
Cardiovascular events are known complications in up to five percent of patients undergoing 
non-cardiac surgery [1]. Furthermore, there is a five-fold increased risk of myocardial infarction 
during the first week after a severe infection [2, 3]. The mechanism behind this increased risk 
is largely unknown but an acute systemic inflammation is a common denominator of surgery 
and severe infection.
Fibrinolysis is a cascade of enzymatic processes leading to degradation of fibrin. This process 
is determined by both plasminogen activators and inhibitors, whereof PAI-1 is believed to be 
the most important inhibitor. Hepatocytes, platelets and vascular endothelial cells are believed 
to be the main producers of PAI-1, but the contribution of different tissues to circulating PAI-1 
may differ in health and disease [4]. Previously, an association between adiposity and impaired 
fibrinolysis was observed [5, 6] and obese diabetic subjects are reported to have increased 
circulating concentrations of PAI-1 [7]. Importantly, both murine and human adipocytes have 
been shown to express PAI-1 mRNA [8-10].
The regulation of gene expression of PAI-1 in adipose tissue (AT) has been investigated in 
numerous studies. Proinflammatory cytokines, such as interleukin (IL)-1β and tumor necrosis 
factor (TNF) increase PAI-1 mRNA in AT in animal models [8, 11, 12] while TNF, IL-1β and 
IL-6 all stimulate upregulation of PAI-1 gene expression in human adipocytes ex vivo [13, 
14]. Other well-known inducers of PAI-1 synthesis in AT are angiotensin II, corticosteroids 
and insulin whereas catecholamines suppress PAI-1 gene expression and synthesis in AT [15-
17]. The current knowledge regarding regulation of PAI-1 in AT is based on animal studies or 
ex vivo experiments on human adipocytes. However, it is unclear whether human adipocytes 
cultured ex vivo adequately represent the situation on a tissue level in vivo. So far, no study has 
described stimulated gene expression and protein synthesis of PAI-1 in vivo in human AT.
We hypothesized that an acute systemic inflammation, through the activation of AT 
inflammatory capacity, induces gene expression and protein production of PAI-1 in vivo. 
Both omental and subcutaneous AT were studied. To our knowledge, we present for the first 
time that an acute systemic inflammation in humans increased gene expression and protein 
synthesis of PAI-1 in AT and that this increase was more prominent in omental compared to 
subcutaneous AT. PAI-1 synthesis in AT due to acute systemic inflammation may be the link 
between inflammation and impaired fibrinolytic activity that might explain the increased risk 
of myocardial infarction seen after surgery or infection.
Methods
Subjects
Patients were eligible if they were planned for elective coronary artery by-pass (CABG) 
surgery and/or aortic or mitral valve replacement according to a standard surgical procedure 
at the Department of Thoracic Surgery at the Karolinska University Hospital, Solna, Sweden. 
Patients were excluded if they had unstable coronary artery disease or were treated with 
corticosteroids. Twenty-two male patients who were planned for open heart surgery underwent 
blood sampling and/or AT biopsies for gene expression and/or immunohistochemistry before 
and after cardiopulmonary bypass (CPB). Basic characteristics regarding all subjects are 
presented in Table 1. Plasma levels of PAI-1 during and up to six hrs after surgery were 
studied in seven patients (age 69 (43-78) yrs, BMI 27.7 (23.2-33.2) kg/m2, CPB 102 (70-
184) min). PAI-1 antigen staining intensity and localization in AT was determined by 
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immunohistochemistry in five patients (age 74 (46-86) yrs, BMI 26.8 (25.2-33.2) kg/m2, 
CPB 87 (74-186) min), with time between first and second AT biopsy 125 (110-210) min. All 
subjects provided written informed consent to participate in the study and the study protocol 
was approved by the Ethics Committee of the Karolinska Institutet. 
Adipose tissue biopsies
Paired AT biopsies of approximately 1 cm3 were taken from 13 patients, whereof both omental 
and subcutaneous AT biopsies from six patients, only omental AT biopsies from one patient 
and only subcutaneous AT biopsies from six patients. The AT biopsies were collected before 
institution of CPB and at 15-20 min after removal of the aortic cross-clamp when the patient 
had been weaned off CPB. The omental AT biopsies were taken through a small opening to 
the abdomen in the bottom of the wound and the subcutaneous AT biopsies were taken deeply 
from the side of the median sternotomy incision.
Plasma analysis of plasminogen activating inhibitor-1 and IL-6
Blood samples were collected in vacutainer ethylendiamid tetraacetic acid (EDTA) tubes 
Table 1. Basic Characteristics
Variable N=22
Age, yrs 69 (43-86)
Sex (men/women) 22/0
Current smokers, N (%)
Former smokers, N (%)
1 (5%)
9 (41%)
Body weight, kg 82 (69-100.4)
BMI, kg/m2 27.4 (21.1-32.4)
CPB, min 94 (47-221)
Time between sample 1 and 2, min 125 (90-285)
Current medication
Acetyl salicylic acid 14 (64%)
Beta blockers 15 (68%)
ACEi 8 (36%)
ARBs 4 (18%)
Calcium antagonists 5 (23%)
Diuretics 9 (41%)
Nitrates 5 (23%)
Statins 13 (59%)
Data presented as median (min and max values), numbers and percent. Body Mass Index 
(BMI), cardiopulmonary bypass (CPB), angiotensin converting enzyme inhibitors (ACEi), 
angiotensin receptor lockers (ARBs).
Ekström et al
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through an indwelling radial artery catheter at the same time as the AT biopsies or every hour 
up to six hrs after start of surgery. All blood samples were centrifuged in room temperature; 
where after plasma was separated and stored at –80ºC. PAI-1 antigen was analysed in 
duplicates using the DuoSet ELISA for human Serpine E1/PAI-1 (R&D Systems, Minneapolis, 
Minnesota, USA). Mean intra-assay, respectively inter-assay coefficient of variation (CV) 
were 6.5% and 5.1%. IL-6 was analyzed using Quantikine Human IL-6 Immunoassay (R&D 
Systems). Intra-assay CV was 10.2%.
Total RNA and cDNA preparation
Biopsies from omental (100-310 mg) and subcutaneous (120-440 mg) AT were immediately 
placed in RNAlater (Ambion, Austin, Texas, USA) and then frozen at –80ºC according 
to the manufacturer’s instructions. Frozen adipose tissue was homogenized and total 
RNA extracted using the RNeasy Mini Kit (QIAGEN, Hilden, Germany) according to 
the supplier’s instructions including a DNase digestion step (QIAGEN) to remove any 
contaminating genomic DNA. An Agilent 2100 Bio analyzer (Agilent Technologies, Santa 
Clara, California, USA) was used to confirm the quality of extracted RNA. A NanoDrop 
ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, Delaware, USA) was 
used to analyse the concentration of RNA. Average yields of total RNA were 3.0 (1.5-5.5) 
μg per 100 mg omental AT wet weight and 2.5 (1.2-5.7) μg per 100 mg subcutaneous AT wet 
weight. Three hundred ng of RNA from each sample was transcribed to complementary DNA 
(cDNA) by Applied Biosystems cDNA-kit, using random primers (Foster City, California, 
USA).
Gene expression studies
To investigate which house keeping gene to use, cDNA from omental AT from four subjects 
was analysed using a TaqMan Human Endogenous Control Plate (Applied Biosystems). To 
analyse AT gene expression, cDNA was mixed with TaqMan® Universal PCR master Mix 
(Applied Biosystems) according to the manufacturer’s instructions. RT-PCR was made using 
relative quantification with PAI-1 (Hs 00167155_m1) as the target gene and Cyclophylin A 
(Hs99999904_m1) as the endogenous control gene. Relative quantification of gene expression 
was calculated with Cyclophylin A as the house keeping gene and when differences in the 
degree of mRNA increase in omental and subcutaneous AT were analysed the first biopsy in 
every paired analysis was used as a reference. Cyclophylin A demonstrated stability during 
inflammation in the endogenous control plate experiment described above with a similar 
cycle threshold value (Ct-value) to the gene of interest.
Immunohistochemical staining of adipose tissue sections
Immunohistochemistry was performed on biopsies from omental and subcutaneous AT to 
investigate staining intensity and localization of PAI-1 antigen. Staining was performed 
using a standard protocol on serial sections from formalin-fixed paraffin-embedded sections. 
Four μm thick serial sections were first deparaffinised and rehydrated with ethanol. Antigen 
retrieval was achieved by microwave irradiation in EDTA buffer, pH 9.0. To block endogenous 
peroxidase activity, sections were treated with 0.3% H
2
O
2
 followed by serum block with 2% 
horse serum and an avidin-biotin blocking step (Vector Laboratories, Burlingame, California, 
USA). Hereafter, sections were incubated for 45 min with a monoclonal mouse anti PAI-1 
antibody (GeneTex, Irvine, California, USA), diluted 1/20. A biotin-labelled horse anti-mouse 
antibody (Vector laboratories) containing 2% normal horse serum was used for detection. 
Phosphate buffer saline was used in all subsequent washes. All sections were developed 
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using a DAB-kit (Vector Laboratories) according to the instructions of the manufacturer. 
Sections were counterstained with Mayer’s haematoxylin.
Evaluation of the immunohistochemical staining of PAI-1 included only subcutaneous AT. A 
semi-quantitative scale from 0 to +++ (where 0 is no positive cells, + is < 25% positive cells, 
++ is 25-75% positive cells and +++ is > 75% positive cells) was used. The evaluation was 
performed blindly by two independent investigators. The agreement between the different 
investigators was > 90 %. The discrepancy was never more than one scale step and consensus 
was obtained by re-evaluation.
Statistical analysis
Data are presented as median (min-max), mean (min-max) or numbers (percent).
Skewed data were log transformed and differences analyzed using student’s t-test. A test for 
linear trend was used to evaluate the differences in plasma levels of PAI-1 over time after 
surgery. The significance level was specified at <0.05.
Results
PAI-1 gene expression in AT
No difference was found in basal PAI-1 gene expression between the two AT depots. However, 
after open heart surgery there was increased mRNA expression of PAI-1 in both omental 
(p=0.028) and subcutaneous AT (p=0.002) (Figure 1). When these figures are analyzed as 
relative quantification using the first biopsy in every paired sample as a reference, the gene 
expression of PAI-1 in omental AT showed a 27-fold increase after surgery whereas a 3-fold 
increased gene expression of PAI-1 was found in subcutaneous AT. The degree of PAI-1 
mRNA increase was higher in omental compared to subcutaneous AT (p=0.021).
Since angiotensin II is a strong inducer of PAI-1 synthesis in AT, we analyzed if the relative 
quantification of stimulated PAI-1 gene expression in subcutaneous AT was depending on 
treatment with angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor 
blockers (ARBs). Six out of twelve subjects were on ACEi/ARB medication all treated 
with maximal doses. However, we could not find any differences in PAI-1 gene expression 
between patients with or without angiotensin II blocking medication (data not shown).
Immunohistochemistry of PAI-1
To confirm inflammation-induced production of PAI-1 at a protein level and to investigate the 
localization of PAI-1 in AT, we stained for PAI-1 antigen in subcutaneous AT biopsies. There 
was a marked increased staining of PAI-1 antigen detected within the vascular endothelium 
as well as in the adventitia of AT vessels after open heart surgery. PAI-1 antigen was also 
detected in the AT interstitium close to AT vessels and in solitary cells in between adipocytes 
(Figure 2 and Table 2).
Plasma levels of IL-6 and PAI-1 during and after open heart surgery
To investigate circulating concentrations of IL-6 and PAI-1 antigen, blood samples were 
collected before and after open heart surgery with a median time of 125 (90-285) min 
between the paired samples. Open heart surgery with CPB induced a more than 25-fold 
increase in plasma IL-6 levels, in median 3.1 pg/ml (3.0-5.9) before and 85.2 pg/ml (31.5-
218.2) after CPB (p<0.001, n=16). No significant differences were found in plasma levels 
of PAI-1 antigen analyzed before and after CPB (Figure 3a). In subjects further investigated 
Ekström et al
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with plasma samples every hour up to six hrs after start of surgery, a positive linear trend was 
found in plasma levels of PAI-1 antigen with an increase after four hrs after start of surgery 
(p<0.001, n=7) (Figure 3b).
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Figure 1. Relative quantification of gene expression of plasminogen activator inhibitor-1 (PAI-1) 
in omental and subcutaneous adipose tissue (AT) before and after open heart surgery.
Relative quantification of gene expression of PAI-1 in relation to the house keeping gene Cyclophylin A 
before and after cardiopulmonary bypass (CPB). No difference was found in basal levels of PAI-1 gene 
expression between the two different AT depots. After open heart surgery there was increased mRNA 
expression of PAI-1 in both omental (p=0.028, n=7) and subcutaneous AT (p=0.002, n=12). Median time 
between samples was 125 (90-285) min.
Before CPB After CPB
Figure 2. Localization of plasminogen activator inhibitor-1 (PAI-1) antigen in subcutaneous 
adipose tissue (AT) before and after open heart surgery.
Representative immunohistochemical analyses of paraffin sections (40x magnification) showing vasculature and 
adipocytes in subcutaneous AT. Strong staining of PAI-1 was detected within the endothelial cells as well as in the 
adventitia, after surgery. PAI-1 antigen was also detected in the AT interstitium close to AT vessels and in solitary 
cell nuclei in between adipocytes (n=5). Cardiopulmonary bypass (CPB).
       Adipose tissue, inflammation and PAI-1 synthesis
7
Table 2. Immunohistochemistry of plasminogen activator inhibitor-1 (PAI-1) in subcuta-
neous adipose tissue biopsies
Before CPB After CPB
+ ++ +++ + ++ +++
PAI-1 4 1 0 0 1 4
A semiquantitative scale from 0 to +++ (0 = no positive cells, + = < 25% positive cells, ++ = 
25-75% positive cells, +++ = > 75% positive cells) was used for the evaluation of the staining of 
plasminogen activator inhibitor-1 (PAI-1). Cardiopulmonary bypass (CPB).
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Figure 3a. Plasma levels of plasminogen activator inhibitor-1 (PAI-1) before and after 
open heart surgery.
No differences were found in plasma levels of PAI-1 antigen (ng/ml) analyzed before and after open 
heart surgery. Median time between samples was 125 (90-285) min (n=16).
Cardiopulmonary bypass (CPB).
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Figure 3b. Plasma levels of plasminogen activator inhibitor-1 (PAI-1) during and up to 
six hrs after start of open heart surgery.
A positive linear trend was found in plasma levels of PAI-1 antigen (ng/ml) with an increase after four hrs 
after start of surgery (p<0.001, n=7).
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Discussion
In the present study we show that an acute systemic inflammation stimulates human AT 
to synthesise PAI-1 in vivo. Open heart surgery stimulates to a markedly increased gene 
expression of PAI-1 in AT, which is significantly higher in omental compared to subcutaneous 
AT. Stimulated PAI-1 protein is located within endothelial cells and adventitia as well as in 
AT interstitium close to AT vessels and in solitary cells in between adipocytes. And last, the 
upregulated PAI-1 gene expression and protein synthesis in AT was followed by an increased 
plasma level of PAI-1 after surgery.
The results of the present study may be questioned as being only a confirmation of earlier 
animal studies and ex vivo experiments on human adipocytes. However, our results are both 
new and of potential major clinical relevance. The increased risk of myocardial infarction seen 
after major surgery does not appear during the surgical procedure itself, characterized by the 
stress from anaesthesiology and surgical trauma, but appears during the early postoperative 
period [1]. The same phenomenon is found after a severe infection with the highest risk of 
myocardial infarction during the first week after onset of infection [2]. Both surgery and 
infection result in a systemic inflammation and the delay in time indicates that a putative 
risk factor for myocardial infarction is synthesized as a response to the acute phase reaction. 
From this point of view molecules that promote thrombus formation at a coronary artery 
plaque rupture, such as PAI-1, would be of major interest. Support for this hypothesis is 
that chronically elevated levels of PAI-1 are associated with spontaneous coronary arterial 
thrombosis in transgenic mice [18] and that increased activity of PAI-1 on the first day after 
CABG has been found to correlate to early vein graft occlusion [19]. However, the origin of 
this increased PAI-1 activity is still largely unknown. In this context, it is highly relevant to 
investigate the in vivo synthesis of PAI-1 in human AT during and after open heart surgery.
In the present study, we clearly demonstrate that human AT rapidly starts to increase the 
synthesis of PAI-1 as a response to the acute systemic inflammation and that the plasma 
levels of PAI-1 antigen increase after surgery, an increase to which the contribution of AT 
PAI-1 production could be highly relevant. This increase in plasma PAI-1 is not due to 
circadian variation since synthesis and plasma levels of PAI-1 is known to exhibit a circadian 
variation with peak levels at 6 am, thereafter the concentrations decrease in plasma [20]. 
Interestingly, our results show a markedly higher PAI-1 gene expression in omental compared 
to subcutaneous AT following surgery which underlines the importance of abdominal fat 
distribution in obesity. The intensified synthesis of PAI-1 in human AT following stimulation 
could severely impair the fibrinolytic activity and may therefore explain the risk of myocardial 
infarction seen after surgery or infection. The PAI-1 response in omental AT following 
stimulation could also be one of the explanations why obesity is an independent risk factor 
for myocardial infarction [21].
It is well known that open heart surgery is followed by an extensive acute systemic inflammation 
with high plasma levels of IL-6 and TNF [22, 23]. Our results confirm these data showing 
marked increased plasma levels of IL-6 already when the patients had been weaned off CPB. 
This acute response is explained by increased gene expression of inflammatory mediators like 
IL-1β, TNF, toll-like receptor-2 and 4 in circulating leukocytes, possibly due to a reaction 
between circulating blood and the synthetic surface of the CPB system [24, 25]. Previously, we 
have demonstrated that open heart surgery with CPB activates AT inflammation through the 
nuclear factor-κB regulatory pathway resulting in down-stream gene expression and synthesis 
of proinflammatory cytokines, chemokines and adhesion molecules [26]. Our results regarding 
increased gene expression of PAI-1 in AT, following open heart surgery indicate that PAI-1 
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synthesis in AT is regulated through the nuclear factor-κB regulatory pathway, congruent with 
a recent review by Kruithof [27] and supported by previous findings from animal studies [11] 
and ex vivo experiments on human adipocytes [9] where lipopolysacharide (LPS) or TNF 
were used as inflammatory stimuli. These characteristics make our model of inflammation 
comparable to LPS or TNF stimulation in animal studies or ex vivo studies on cultured human 
adipocytes and therefore give us the opportunity to investigate the in vivo effects of a strong 
acute systemic inflammation in humans.
Previously, ex vivo experiments have shown that angiotensin II stimulates PAI-1 gene expression 
in human adipocytes and that ACEi/ARBs were able to completely prevent this stimulation 
[17]. The use of angiotensin II inhibitors has also been reported to alter fibrinolytic activity 
during open heart surgery [28]. However, we could not find any differences in stimulated 
PAI-1 gene expression between patients with or without ACEi/ARBs treatment in our study. 
We can conclude that angiotensin II is not a likely major stimulatory factor of PAI-1 synthesis 
in AT during acute systemic inflammation.
In the present study, we demonstrate a markedly higher degree of upregulation of PAI-1 gene 
expression in omental compared to subcutaneous AT following an acute systemic inflammation. 
However, we found no significant differences in basal levels between the two AT depots. The 
results confirm earlier ex vivo studies by Alessi and Gottschling-Zeller who also demonstrated 
higher PAI-1 synthesis in omental versus subcutaneous cultured adipocytes following 
stimulation [9, 29]. These findings have been contradicted by another study demonstrating a 
lower ex vivo secretion rate of PAI-1 in omental compared to subcutaneous AT [30]. However, 
this study investigated PAI-1 production in non-stimulated conditions. Two additional studies 
have measured basal arterio-venous concentration differences of PAI-1 antigen across omental 
and subcutaneous AT but neither of them could show any significant differences across 
different AT beds in vivo [4, 31]. However, Yudkin and co-workers found a greater arterio-
venous difference in PAI-1 activity in diabetic compared to nondiabetic subjects but the groups 
were small and the results were not paralleled by PAI-1 antigen concentrations. Nevertheless, 
the contribution of different AT beds to circulating PAI-1 could differ in health and disease.
We found a markedly increased gene expression of PAI-1 and a strong staining of PAI-1 
antigen in AT biopsies taken already when the patient had been weaned off CPB, while 
plasma levels of PAI-1 did not increase until hours after surgery. This clearly suggests that 
the PAI-1 protein detected in AT by immunohistochemistry does not merely reflect plasma 
levels. It suggests that PAI-1 synthesis in AT significantly contributes to the later increase 
in plasma concentrations of PAI-1. In this context, our results emphasize the importance 
of omental compared to subcutaneous AT. The kinetics of PAI-1 synthesis within omental 
AT has never been investigated in detail but results from experiments on cultured human 
adipocytes showed increased synthesis of PAI-1 antigen five hrs after stimulation [9].
Limitations
In our study we only measured plasma concentrations of PAI-1 antigen and not PAI-1 activity 
or t-PA to which PAI-1 partly is found in complex. However, there is a close association 
between antigen levels and activity [32]. Furthermore, measuring both gene expression and 
protein levels of PAI-1 antigen could be more relevant than analyzing PAI-1 activity alone. 
Another limitation is that there are other sources of plasma levels of PAI-1, such as activated 
platelets. However, PAI-1 in platelets is already synthesized and ready to be released whenever 
the platelets are activated. Most likely, an increased plasma level of PAI-1 due to activated 
platelets would have been detected earlier, possibly already during surgery. A third limitation 
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may be the low numbers of AT, in particular omental, biopsies and the potential risk of local 
tissue trauma when taking the biopsies. However, the use of paired biopsies before and after 
surgery minimizes the risk of inter-individual variation compensating for the low numbers. 
To avoid local stress from the surgical trauma the omental AT biopsies were taken through a 
small opening to the abdomen in the bottom of the wound and the subcutaneous AT biopsies 
were taken deeply from the side of the median sternotomy incision. A fourth limitation is the 
low number of subjects with plasma samples taken after surgery. However, our result of an 
increase in circulating PAI-1 after open heart surgery is supported by the study of Moor and 
co-workers who showed increased PAI-1 activity the day after surgery [19].
Our study clearly demonstrates that increased PAI-1 synthesis in AT during an acute phase 
response is one possible link between inflammation and myocardial infarction. Other 
systems important for coagulation and haemostasis may also react upon an acute systemic 
inflammation. Increased plasma levels of activated factor VII has been shown following a 
low grade acute inflammation [33] and interactions between bacterial pathogens and platelet 
receptors which result in platelet activation have also been demonstrated [6, 34].
In conclusion, we present for the first time in vivo that an acute systemic inflammation 
increased gene expression and protein synthesis of PAI-1 in human AT and that this increase 
was more prominent in omental compared to subcutaneous AT. PAI-1 synthesis in AT due to 
acute systemic inflammation may be the link between inflammation and impaired fibrinolytic 
activity that might explain the increased risk of acute myocardial infarction seen after surgery 
or infection.
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Abstract
Background
Adipose tissue (AT) is not only an energy-depot but also an organ producing inflammatory and 
metabolically active cytokines. Modulation of these adipokines during an acute inflammatory 
response is of considerate interest as they are suggested to have an important role also in 
chronic inflammation and in the development of atherosclerosis. However, the regulation of 
adipokines in the early phase of acute inflammation in humans is poorly understood. In this 
study acute inflammation was stimulated by vaccination and open heart surgery respectively, 
with the aim to investigate the effects on adiponectin and leptin synthesis.
 
Materials and methods
Adiponectin and leptin were measured as plasma levels after vaccination, respectively as by 
gene expression in omental and subcutaneous AT after surgery. 
Results
Plasma levels of interleukin (IL)-6 increased 3-4-fold after vaccination whereas IL-6 
increased 30-folds after open heart surgery. Neither plasma levels of adiponectin nor leptin 
were changed after vaccination. The gene expression levels of adiponectin or leptin were 
unaltered in both omental and subcutaneous AT after surgery.
Conclusion
We found no evidence that an acute systemic inflammation could affect synthesis of 
adiponectin or leptin indicating that these two adipokines are not key elements in the early 
acute-phase response.
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Introduction
Adipose tissue (AT), classically thought to be merely a storage place for energy, has been 
shown to produce inflammatory and metabolically active cytokines. Chronic activation 
of innate immune responses within AT characterizes development of insulin resistance 
and atherosclerosis (1). Recently, adiponectin and leptin, two adipokines that primarily are 
synthesized by adipocytes, have attracted considerable attention because inflammation has been 
suggested to modulate adipokine levels. However, the regulation of adiponectin and leptin is 
complex and the knowledge about their synthesis within the early onset of inflammation still is 
poorly understood. Acute inflammatory effects on AT are, in this context, of particular interest 
because of the role of adipokines in the development of atheroscleroisis.
Adiponectin decreases with increasing obesity and has been described as anti-atherogenic 
including its positive effects on insulin sensitivity, whereas leptin is involved in the central 
regulation of appetite (1-3). A rapid weight loss in obese individuals decreases plasma levels 
of leptin while levels of adiponectin do not change (4). However, a longer period of weight 
loss and lifestyle changes increases adiponectin levels (5). Despite that plasma levels of leptin 
were increased and positively correlated with proinflammatory cytokines during sepsis (6) 
and further associated with increased survival of sepsis (7), few studies have addressed the 
influence of innate immunity on adiponectin and leptin in humans. The results of previous 
studies have been conflicting. One previous in vitro study has demonstrated that tumor necrosis 
factor (TNF) has dual effects on AT leptin release and synthesis with increased release of 
preformed leptin but inhibition of AT leptin synthesis (8). Anderson and coworkers have recently 
shown that leptin levels in plasma increased but there were no changes in adiponectin levels 
after lipopolysaccharide (LPS) injection in vivo. Moreover, on a gene expression level, only 
adiponectin was affected with suppressed mRNA expression in subcutaneous AT (9). Another 
study showed no effect of inflammation, caused by subarachnoidal hemorrhage, on adiponectin 
and leptin mRNA in subcutaneous AT (10). Methodological differences between these studies 
could partly explain differences in the results and therefore we don’t know if adiponectin and 
leptin are important in the acute-phase response or how they are regulated. The present study 
is a sub-study to two earlier studies where we used two different models of inflammation: 
vaccination against salmonella typhi and open heart surgery, which both stimulate to an acute 
systemic inflammation through activation of the NF-κB regulatory pathway (11, 12). 
Material and methods
Subjects
Eighteen healthy volunteers (sixteen men and two postmenopausal women) with a median age 
of 60 (49-67) years and BMI of 26.8 (19.8-38.8) were included in the vaccination study. Their 
basic characteristics have been described in detail (11)  and are in brief presented in Table 1. 
Nine of the study subjects were vaccinated against Salmonella typhi (typhim Vi, Sanofi Pasteur 
MSD, Sweden), whereas the remaining subjects served as controls. Subjects arrived at 7 a.m. 
to the Karolinska University Hospital after fasting overnight. Venous blood samples were 
obtained after 0, 4, 8, 12 and 24 hrs. After vaccination and/or first blood sample participants 
had a light breakfast including a sandwich with cheese and a cup of coffee or tea with sugar and 
milk as preferred. 
The patients in the open heart surgery study were eligible if they were planned for elective 
coronary artery by-pass (CABG) surgery and/or aortic or mitral valve replacement according 
to a standard surgical procedure at the Department of Thoracic Surgery at the Karolinska 
University Hospital, Solna, Sweden. Patients were excluded if they had unstable coronary 
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artery disease or were treated with corticosteroids. Nine male patients, with a median age of 65 
(43-85) years and BMI of 27.7 (21.1-32.4), were included for the gene expression study and 
underwent AT biopsies and blood samples before and after cardiopulmonary bypass (CPB) as 
described (12). Basic characteristics are presented in Table 1.
All subjects provided written informed consent to participate in the study and the study protocol 
was approved by the Ethics Committee of Karolinska Institutet. 
Plasma analyses
Plasma IL-6 sampling before and after vaccination and open heart surgery, respectively has 
been described in detail (11, 12). In brief, in the vaccination study venous blood samples were 
obtained after 0, 4, 8, 12 and 24 hrs, without an indwelling venous catheter. In the open heart 
surgery study the first blood sampling was made after approximately 30-40 min of surgery, 
before start of cardiopulmonary bypass (CPB). The second blood sampling was made after the 
CPB had been turned off with a median time of 125 (90-285) min between the paired samples. 
The blood samples in the open heart surgery study were obtained from an indwelling radial 
Table 1. Basic characteristics.
Variable
 Vaccination study Open heart surgery 
study
                                    
n=9
       Vaccinated                     Controls
            n=9                               n=9
Age, yrs 59 (56-66) 60 (49-67) 65 (43-85)
Sex (men/women) 8/9 (89%) 8/9 (89%) 9/0
Current smokers, N
Former smokers
2 (22%)
5 (56%)
1 (11%)
4 (44%)
1/9 (11%)
4/9(44%)
Body weight, kg 93 (60-127) 90 (64-109) 79.9 (62.5-92.7)
BMI, kg/m2 25 (21-38.8) 28.2 (19.8-32.5) 27.7 (21.1-32.4)
CPB, min NA NA 98 (50-221)
Time between sample 1 and 
2, min
NA NA 125 (90-285)
History of Diabetes NA NA 1/9 (11%)
Current medication:
Acetyl salicylic acid NA NA 7/9 (78%)
Beta blocker NA NA 2/9 (22%)
ACEi NA NA 2/9 (22%)
ARBs NA NA 2/9 (22%)
Calcium antagonists NA NA 3/9 (33%)
Diuretics NA NA 2/9 (22%)
Nitrates NA NA 4/9 (44%)
Statins NA NA 8/9 (89%)
Data presented as median (min and max values), numbers and percent. 
No differences were found between vaccinated and controls in the vaccination study.
Angiotensin converting enzyme inhibitor (ACEi), angiotensin receptor blockers (ARBs), Body mass 
index (BMI), cardiopulmonary bypass (CPB), data not applicable (NA). 
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artery catheter. All blood samples were collected in vacutainer ethylendiamid tetraacetic acid 
(EDTA) tubes and centrifuged in room temperature; where after plasma was separated and 
stored at –80ºC.
Plasma levels of adiponectin and leptin in the vaccination study were analyzed in duplicates 
using double-antibody radioimmunoassays (RIA) (Linco, St. Louis, MO, USA). CV for 
adiponectin was 15.2% at low (2–4 µg/mL) and 8.8% at high (26–54 µg/mL) levels. CV for 
leptin was 4.7% at both low (2–4 ng/mL) and high (10–15 ng/mL) levels. 
Plasma levels of IL-6 in the vaccination study were determined in duplicates using a high 
sensitive ELISA (R&D Systems, Minneapolis, Minnesota, USA) with an intra-assay CV of 
9.5%. Plasma levels of IL-6 in the open heart surgery study were analyzed in duplicates using 
one Quantikine Human IL-6 Immunoassay plate (R&D Systems) with an intra-assay coefficient 
of variation (CV) of 10.2%. 
Adipose tissue biopsies
Paired AT biopsies of approximately 1 cm3 were taken from nine patients, whereof both 
omental and subcutaneous AT biopsies from six patients, only omental AT biopsies from one 
patient and only subcutaneous AT biopsies from two patients. The AT biopsies were collected 
at the same time as the paired blood samples, before institution of CPB and at 15-20 min after 
removal of the aortic cross-clamp when the patient had been weaned off CPB. The omental AT 
biopsies were taken through a small opening to the abdomen in the bottom of the wound and the 
subcutaneous AT biopsies were taken deeply from the side of the median sternotomy incision.
Gene expression studies
The protocol for total mRNA and cDNA preparation has been described in detail (12). To 
investigate which house keeping gene to use, cDNA from omental AT from four subjects was 
analyzed using a TaqMan Human Endogenous Control Plate (Applied Biosystems, Foster 
City, California, USA). To analyze AT gene expression, cDNA was mixed with TaqMan® 
Universal PCR master Mix (Applied Biosystems) according to the manufacturer’s instructions. 
RT-PCR was made using a custom made Low Density Array (Applied Biosystems) with 
Adiponectin (Hs00605917_m1) and Leptin (Hs00174877_m1) as target genes and Cyclophylin 
A (Hs99999904_m1) as an endogenous control gene, with a RT-PCR protocol according to 
the manufacturer’s instructions. Relative quantification of gene expression was calculated with 
Cyclophylin A as the house keeping gene using the first biopsy in every paired analysis as a 
reference. Cyclophylin A demonstrated stability during inflammation in the endogenous control 
plate experiment described above with a similar cycle threshold value (Ct-value) to the gene 
of interest.
Statistics
Data are presented as median (min-max) or numbers (percent). Differences between continuous 
variables have been analyzed using Mann-Whitney U-test or Wilcoxon signed-rank test. The 
significance level was specified at <0.05.
Results
Systemic Inflammation
Plasma IL-6 levels after vaccination and open heart surgery have previously been reported (11, 
12). After vaccination the plasma levels of IL-6 increased 3-4-fold with a significant difference 
at 8 hours after vaccination, while open heart surgery resulted in a 30-fold increase in plasma 
levels of IL-6.
         Adipokines in acute-phase response
5
Adipokines
Plasma levels of adiponectin and leptin were unaltered after vaccination, showing similar 
levels as in control group (Figure 1). Relative mRNA gene expression after open heart surgery, 
expressed as change from baseline was analyzed in both omental and subcutaneous AT biopsies. 
Neither adiponectin nor leptin mRNA from omental AT did change after open heart surgery 
with a median time of 125 (90-285) min between the biopsies. Similar results were obtained for 
subcutaneous AT (Figure 2). 
Figure 1. Plasma levels of adiponectin and leptin before and after vaccination
Box plots of plasma levels of adiponectin (a) and leptin (b) in healthy subjects vaccinated 
against Salmonella typhi (n=9, black boxes) and controls (n=9, open boxes).
a. Plasma levels of Adiponectin (μg/ml)
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Figure 2. Relative adipose tissue mRNA gene expression after open heart surgery 
expressed as change from baseline
Relative quantification of adiponectin and leptin in (a) omental adipose tissue (AT) and (b) 
subcutaneous AT. Relative quantification expressed in relation to the house keeping gene 
Cyclophylin A, using the first biopsy in every paired analysis as a reference and a logarithmic 
scale. Omental AT (n=7) and subcutaneous AT (n=8).
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0.3
0.2
0.1
0.0
-0.1
-0.2
-0.3
(a) Omental adipose tissue (b) Subcutaneous adipose tissue
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Discussion
The results of the present study showed that an acute systemic inflammation did not influence 
adiponectin and leptin synthesis, neither measured as plasma concentrations after vaccination, 
nor measured as mRNA gene expression in omental or subcutaneous AT after open heart 
surgery.
When circulating levels of adiponectin were investigated in patients with acute myocardial 
infarction, a reduction of adiponectin was found to inversely correlate to C-reactive protein 
with a decrease 24 hrs after myocardial infarction (13). Furthermore, following open heart 
surgery, plasma levels of leptin do not increase until 24 hrs post-surgery (14). In our study 
we did not find any differences in plasma levels of adiponectin or leptin up to 24 hrs after 
vaccination. One possible explanation is that vaccination, that resulted in increased gene 
expression of TNF in peripheral blood mononuclear cells after four hrs and doubled plasma 
levels of IL-6 after eight hrs (11), might have been too weak as a model of inflammation. 
We have previously reported on a very rapid onset of a strong innate immune response 
in AT following systemic inflammation induced by open heart surgery (12), therefore we 
investigated adiponectin and leptin on a gene expression level AT after surgery. However, 
in the present study we could not find any changes in mRNA of these adipokines neither in 
omental nor in subcutaneous AT after surgery. Possible reasons for this could be either that 
that we have analyzed the AT gene expression too early or that these adipokines are not key 
elements in the acute-phase response. Our results do not exclude that adiponectin and leptin 
levels change later in the inflammatory reaction.
Previously, in vitro experiments on human macrophages have demonstrated inhibitory 
effects of adiponectin on LPS-induced production of TNF, indicating that adiponectin is an 
important regulator of the immune system (15). However, in that study adiponectin did not 
affect IL-6 expression in macrophages which indicates that IL-6 may have inhibitory effects 
on adiponectin in AT (16). Interestingly, we could not find any suppressed gene expression 
of adiponectin despite a marked upregulation of IL-6 mRNA in AT early after open heart 
surgery, however, a late effect could not be excluded.
When leptin synthesis has been studied in cultured human subcutaneous adipocytes it has 
been demonstrated that TNF attenuated mRNA gene expression but in contrast, induced an 
increased release (8). Furthermore, another in vitro experiment by Bruun and coworkers 
have shown that the proinflammatory cytokines IL-1β and TNF both decreased leptin gene 
expression and protein production but interestingly IL-1β was found to elicit an early release 
of leptin (17). The results of these two in vitro studies suggest a pre-formed pool of leptin 
in human AT with a paracrine regulation to which IL-1β and TNF could be important key 
regulators. However, this pool has not yet been identified and it is not clear whether human 
adipocytes stimulated in vitro adequately represent the situation on a tissue level in vivo. In 
the present study we could not find any influences on plasma levels of leptin after vaccination. 
Nor after open heart surgery there were any changes in leptin gene expression neither in 
omental nor in subcutaneous AT.  
There are also some recent in vivo studies that have focused on both adiponectin and leptin 
synthesis in relation to acute inflammation. Anderson and coworkers showed that leptin levels 
increased in plasma after LPS injection but adiponectin levels remained unchanged. On a gene 
expression level only adiponectin was affected with suppressed expression in subcutaneous 
AT, whereas there was only a trend towards increased gene expression of leptin (9). The 
study by Jernås and coworkers showed no effect of inflammation, caused by subarachnoidal 
haemorrhage, on adiponection and leptin mRNA gene expression in subcutaneous AT (10). 
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The results of our study support the findings by Jernås and coworkers (10). Furthermore, our 
results extend previous studies by also analyzing gene expression in omental AT. The reason 
for the discrepant results is not clear but methodological issues have to be considered. First, 
the stimulus to inflammation was different between the studies. Anderson and coworkers (9) 
used LPS whereas we (in the open heart surgery study) and Jernås and coworkers (10) used 
tissue damage and in our case, possibly also CPB to stimulate innate immunity. All of these 
are strong stimuli but might activate different subsets of cells, including macrophages in AT. 
It can be argued that the inflammatory stimulus on AT was similar in our study compared with 
the study by Anderson and coworkers (9) since we had a similar strong gene expression of 
IL-6 (12). Also the time-frames were different with the possibility that we, in the open heart 
surgery study investigated gene expression in AT too early (approximately two hrs) whereas 
Jernås and coworkers (10) investigated gene expression too late (days). Finally, there is 
a possibility that the gene expression results in the study by Anderson and coworkers (9) 
might be false due to up-regulation of β-actin by inflammation rather than down-regulation 
of adiponectin. In our study, we also tested the results using other house-keeping genes than 
Cyklophyllin A without changing the negative result (data not shown). 
One limitation in the present study may be the low number of patients investigated in the 
gene expression experiment but we used paired AT biopsies which minimize a possible 
inter-individual variation. Furthermore, the size of the study group was large enough to 
demonstrate a very rapid onset of a marked innate immune response in AT following systemic 
inflammation induced by open heart surgery (12).
Both models of stimulated inflammation used in this study activate inflammation through 
the nuclear factor-κB pathway (11, 12) and interestingly, none of the models were shown to 
have any influence on the synthesis of adiponectin or leptin which indicates that the nuclear 
factor-κB pathway is not involved in the regulation of these two adipokines in an acute-phase 
response. This is also supported by a recent study by Diez and co-workers who showed that 
leptin was not found to act as an inflammatory reactant but more as a marker of nutritional 
status in patients with pneumonia (18).
In conclusion, despite the use of two models of stimulated in vivo systemic inflammation we 
found no evidence of an early regulation of adiponectin and leptin synthesis, indicating that 
these two adipokines are not key elements in an acute systemic inflammation in humans.
Ekström et al
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Background
Adipose tissue (AT) is not only a store of energy but an endocrine organ with capacity 
to produce and release proinflammatory mediators into the circulation. Obesity is an 
inflammatory disease, with increased circulating levels of interleukin (IL)-6, due to 
synthesis in AT. As current knowledge regarding AT inflammation, to a great extent 
relies on studies done in non-stimulated or chronic inflammatory conditions, it is 
important to add data from human studies, using different models of induced acute 
systemic inflammation. As obesity is becoming a global disease it is also an increasing 
risk factor for cardiovascular disease (CVD). CVD events are known complications 
after surgery and severe infection. The mechanisms behind this increased risk are still 
poorly understood but an acute systemic inflammation is a common denominator.
Methods and results
Study I: We investigated if a standardised systemic inflammation, induced by a 
vaccination against Salmonella typhi, would trigger inflammatory gene expression in 
AT. Healthy volunteers were investigated whereof half of them were vaccinated. Plasma 
levels of IL-6 increased 8 hrs after vaccination. In peripheral blood mononuclear cells 
we found an increased tumour necrosis factor gene expression after 4 hrs. In AT there 
were no differences in gene expression between the two groups.
Study II: Gene expression and production of inflammatory mediators in different AT 
depots were investigated after open heart surgery. Plasma levels of IL-6 increased 25-
fold. In both omental and subcutaneous AT, we found a strong upregulation of nuclear 
factor-κB regulated genes. Immunohistochemistry (IHC) showed staining for E-selectin 
associated with a high number of macrophages in close contact with and in the vascular 
wall. Increased levels of IL-6 were detected in microdialysate from subcutaneous AT.
Study III: Plasminogen activator inhibitor-1 (PAI-1) synthesis in AT was studied after 
acute systemic inflammation, induced by open heart surgery. Gene expression of 
PAI-1 increased 27-fold in omental AT and 3-fold in subcutaneous AT. After surgery, 
IHC staining showed localization of PAI-1 antigen within endothelial cells, in the 
AT interstitium close to AT vessels and in solitary cells between the adipocytes. The 
upregulated gene expression and protein synthesis in AT was followed by increased 
concentrations of PAI-1 antigen in plasma.
Study IV: This was a sub-study of study I and II, with the aim to investigate the effects 
of an acute systemic inflammation on adiponectin and leptin synthesis. Neither plasma 
levels of adiponectin nor leptin were changed after vaccination. Gene expression of 
adiponectin and leptin were unaltered in both omental and subcutaneous AT after 
surgery.
Conclusion
Vaccination stimulates a mild systemic inflammation but does not trigger proinflammatory 
gene expression in AT. Open heart surgery induced a strong inflammatory response in 
both omental and subcutaneous AT including adhesion of macrophages to an activated 
endothelium and release of IL-6 from AT interstitium. We found no evidence that an 
acute systemic inflammation could affect synthesis of adiponectin or leptin indicating 
that these two adipokines are not key elements in the early acute-phase response. There 
was a markedly increased gene expression and protein synthesis of PAI-1 in human AT 
after open heart surgery. The increase was most prominent in omental AT. PAI-1 synthesis 
in AT, following acute systemic inflammation, may be the link between inflammation 
and impaired fibrinolysis that might explain the increased risk for myocardial infarction 
after surgery or infection.
